Source document: https://docs-lawep.s3.us-east-2.amazonaws.com/1698829769000.pdf (New Zealand)
Version as at 5 October 2023 Misuse of Drugs Regulations 1977 (SR 1977/37) Denis Blundell, Governor-General Order in Council At the Government House at Wellington this 8th day of March 1977 Present: His Excellency the Governor-General in Council Pursuant to the Misuse of Drugs Act 1975, His Excellency the Governor-General, acting by and with the advice and consent of the Executive Council, hereby makes the following regulations.
Contents Part 1 Preliminary 1 2 2A Title and commencement Interpretation Transitional, savings, and related provisions Page 4 4 7 Note The Parliamentary Counsel Office has made editorial and format changes to this version using the powers under subpart 2 of Part 3 of the Legislation Act 2019.

Note 4 at the end of this version provides a list of the amendments included in it.

These regulations are administered by the Ministry of Health.
1 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 Part 2 Licences Application for and issue of licences Fees inclusive of GST Application to industrial hemp Application to medicinal cannabis products Dealers’ licences Endorsements on dealers’ licences Duration and renewal of dealers’ licences Import and export licences Licences to cultivate Licences to possess controlled drugs Licences not to be assigned Revocation of licences Part 3 Permissions Effect of this Part Authority for designated prescriber nurses, designated prescriber pharmacists, midwives, and nurse practitioners to prescribe certain controlled drugs Permissions relating to prescription of controlled drugs authorised under regulation 12A Authority for designated pharmacist prescribers to prescribe certain controlled drugs [Revoked] Manufacture and use in manufacture General authority of licensees to possess Authority to import CBD products [Revoked] Hospitals and other institutions Seeds and fruit of prohibited plants Special authority for masters of vessels Special authority for captains of aircraft First-aid kits Supply and administration of controlled drugs without prescription Part 4 Restrictions and conditions Restrictions on application of section 8 of Act, etc Restriction on supply of certain controlled drugs Conditions of supply to agents Supply on prescription Labelling of containers Exemptions from regulation 25 Restrictions on sizes of containers Controlled drugs used for exempted drugs 7 9 9 9 9 11 11 12 13 14 14 14 15 15
drugs 3A 3B 3C 12A 12B 12C 13 14 14A 25A 26 27 2 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 28 Custody of controlled drugs 29 30 31 31A 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 49A 50 51 52 52A 53 54 Part 5 Prescriptions for controlled drugs General requirements in relation to prescriptions Exemption for certain prescriptions Restrictions on supply on prescription
 Exceptions to restrictions in regulation 31(1) Verification of prescriptions Retention of paper prescriptions Emergencies Duty to supply information Special provisions for hospitals Part 6 Registers, records, and returns Pharmacists and dispensing practitioners Other dealers Form of records Entries in Controlled Drugs Register and Prescription Book Exemption of practitioners Retention of records Stocktaking Hospital records Ward Books Application of other regulations to hospital records Returns of wholesale transactions Exemptions from Part 6 Part 7 Miscellaneous provisions Notification of import and export of certain controlled drugs [Revoked] Notification of stock Restrictions on advertising Communications through Medical Officer of Health Penalty Application of regulations to drug and substance checking service providers and their users Transitional [Revoked] Revocations Schedule 1AAA Transitional, savings, and related provisions Schedule 1AA Licence fees Part 1 r 1 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 Schedule 1A Controlled drugs that designated prescriber nurses may prescribe in certain circumstances Schedule 1B Controlled drugs that designated prescriber pharmacists may prescribe Schedule 1C Controlled drugs that midwives may prescribe Schedule 1 Schedule 2 Regulations revoked Regulations Part 1 Preliminary 55 56 58 59 61 Title and commencement These regulations may be cited as the Misuse of Drugs Regulations 1977.
Except as provided in regulation 28(6), these regulations shall come into force on 1 June 1977.

Regulation 1(2): amended, on 1 June 1977, by regulation 2 of the Misuse of Drugs Regulations 1977, Amendment No 1 (SR 1977/135).
Interpretation In these regulations, unless the context otherwise requires,— Act means the Misuse of Drugs Act 1975 advertisement means any words, whether written, printed, or spoken, and any pictorial representation or design, used or appearing to be used to promote the sale of a controlled drug; and includes any trade circular, any label, and any advertisement in a trade journal container, in relation to a controlled drug, means the bottle, jar, box, packet, or other receptacle that contains or is to contain the drug, not being a capsule, cachet, or other article in which a controlled drug is or is to be administered; but, where any such receptacle is or is to be contained in another receptacle, does not include the latter receptacle controlled drug prescriber means— (a) (b) a medical practitioner: a dentist: 1 (1) (2) 2 (1) 4 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 1 r 2 (c) (d) (e) (f) (g) a nurse practitioner: a midwife: a designated prescriber nurse: a designated prescriber pharmacist: a veterinarian to deal in means to manufacture, to use in manufacture, to supply, or to admin‐ ister dealer’s licence means a licence authorising a person to deal in controlled drugs designated prescriber nurse means a registered nurse who— (a) (b) is a designated prescriber; and is acting within his or her scope of practice designated prescriber pharmacist means a pharmacist who— (a) (b) is a designated prescriber; and is acting within his or her scope of practice Director-General means the
 person for the time being holding the office of Director-General of Health under the Health Act 1956; and includes any person to whom subclause (2) for the time being applies exempted drug means a controlled drug for the time being named or described in Part 6 of Schedule 3 of the Act hospital means a hospital care institution within the meaning of section 58(4) of the Health and Disability Services (Safety) Act 2001 industrial hemp has the same meaning as in the Misuse of Drugs (Industrial Hemp) Regulations
 2006 licence means a licence granted under these regulations; and licensed and licensee have corresponding meanings manager, in relation to a hospital, includes an acting manager manufacture means any process by which controlled drugs may be obtained, other than the separation of opium, coca leaves, cannabis resin, cannabis fruit, or cannabis seed from plants; and includes refining and the transformation of controlled drugs into other controlled drugs name, in relation to a controlled drug, means the name, if any, by which the controlled drug is for the time being called in any Schedule of the Act; and named has a corresponding meaning officer means a person for the time being authorised by the Minister to exer‐ cise the powers referred to in section 19(1) of the Act 5 Part 1 r 2 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 partially exempted drug means a controlled drug that is either of the follow‐ ing: (a) a controlled drug for the time being named or described in clauses 1 to 5 of Part 3 of Schedule 3 of the Act: (b) a preparation of pseudoephedrine that is— (i) (ii) named or described in clause 6 of Part 3 of Schedule 3 of the Act; or in a modified or sustained release formulation that delivers no more than 240 mg of pseudoephedrine in a 24-hour period pharmacy means a place where pharmacy practice is carried on pharmacy practice has the same meaning as in section 2(1) of the Medicines Act 1981 practitioner means a medical practitioner,
 dentist, or veterinarian principal display panel means the part of a label that is most likely to be dis‐ played, presented, shown, or examined under ordinary or customary conditions of display for retail sale, and, if such likelihood is equal in respect of 2 or more panels, means every such panel registered nurse means a health practitioner who— (a) is, or is deemed to be, registered with the Nursing Council of New Zea‐ land continued by section 114(1)(a) of the Health Practitioners Compe‐ tence Assurance
 Act 2003 as a practitioner of the profession of nursing and whose scope of practice permits the performance of registered nurse functions; and (b) holds a current practising certificate.
(2) Any power conferred on the Director-General by these regulations may be exercised by any officer of the Ministry of Health nominated by the Director- General for the purpose subject to the general control of the Director-General.

Regulation 2(1) CBD product: revoked, on 18 December 2018, by section 12(2) of the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 (2018 No 54).
Regulation 2(1) controlled drug prescriber: inserted, on 1 July 2014, by regulation 4(2) of the Mis‐ use of Drugs Amendment Regulations 2014 (LI 2014/199).

Regulation 2(1) dentist: revoked, on 1 July 2014, by regulation 4(1)(a) of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).

Regulation 2(1) designated pharmacist prescriber: revoked, on 1 July 2014, by regulation 4(1)(b) of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).
Regulation 2(1) designated prescriber nurse: replaced, on 1 July 2014, by regulation 4(2) of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).

Regulation 2(1) designated prescriber nurse: amended, on 20 September 2016, by regulation 4(1) of the Misuse of Drugs Amendment Regulations 2016 (LI 2016/139).

Regulation 2(1) designated prescriber pharmacist: inserted, on 1 July 2014, by regulation 4(2) of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).
6 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 2 r 3 Regulation 2(1) hospital: replaced, on 1 October 2002, by section 58(3) of the Health and Disability Services (Safety) Act 2001 (2001 No 93).

Regulation 2(1) industrial hemp: inserted, on 1 August 2006, by regulation 4 of the Misuse of Drugs Amendment Regulations 2006 (SR 2006/164).

Regulation 2(1) manager: inserted, on 1 July 1993, by regulation 2(1) of the Misuse of Drugs Regu‐ lations 1977, Amendment No 10 (SR 1993/157).
Regulation 2(1) medical practitioner: revoked, on 1 July 2014, by regulation 4(1)(d) of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).

Regulation 2(1) midwife: revoked, on 1 July 2014, by regulation 4(1)(e) of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).

Regulation 2(1) nurse: revoked, on 20 September 2016, by regulation 4(2) of the Misuse of Drugs Amendment Regulations 2016 (LI 2016/139).
Regulation 2(1) partially exempted drug: replaced, on 15 October 2004, by regulation 3 of the Mis‐ use of Drugs (Ephedrine and Pseudoephedrine) Amendment Regulations 2004 (SR 2004/315).

Regulation 2(1) pharmacist: revoked, on 1 July 2014, by regulation 4(1)(f) of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).

Regulation 2(1) pharmacy: inserted, on 18 September 2004, by section 175(3) of the Health Practi‐ tioners Competence Assurance Act 2003 (2003 No 48).
Regulation 2(1) pharmacy practice: inserted, on 18 September 2004, by section 175(3) of the Health Practitioners Competence Assurance Act 2003 (2003 No 48).

Regulation 2(1) practitioner: amended, on 1 July 2014, by regulation 4(3) of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).

Regulation 2(1) practitioner: amended, on 22 December 2005, pursuant to section 95 of the Veterin‐ arians Act 2005 (2005 No 126).
Regulation 2(1) private hospital: revoked, on 1 July 1993, by regulation 2(2) of the Misuse of Drugs Regulations 1977, Amendment No 10 (SR 1993/157).

Regulation 2(1) registered midwife: revoked, on 18 September 2004, by section 175(3) of the Health Practitioners Competence Assurance Act 2003 (2003 No 48).

Regulation 2(1) registered nurse: inserted, on 20 September 2016, by regulation 4(3) of the Misuse of Drugs Amendment Regulations 2016 (LI 2016/139).
Regulation 2(2): amended, on 1 July 1993, by regulation 2(3) of the Misuse of Drugs Regulations 1977, Amendment No 10 (SR 1993/157).

2A Transitional, savings, and related provisions The transitional, savings, and related provisions set out in Schedule 1AAA have effect according to their terms.

Regulation 2A: inserted, on 16 June 2023, by regulation 4 of the Misuse of Drugs Amendment Regu‐ lations 2023 (SL 2023/129).
Part 2 Licences 3 (1) Application for and issue of licences Except with the written approval of the Minister given in relation to a particu‐ lar case, no licence may be granted to deal in a controlled drug for the time being named in— 7 Part 2 r 3 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 (a) (b) (c) Schedule 1 of the Act: Part 1 of Schedule 2 of the Act: Part 1 of Schedule 3 of the Act.
(1A) However, the approval of the Minister under subclause (1) is not required for the grant of a licence to deal in— (a) cocaine, or in anything to which any of clauses 2 to 5 of Schedule 1 of the Act for the time being applies in relation to cocaine: (b) morphine or opium, or in anything to which any of clauses 2 to 5 of Part 1 of Schedule 2 of the Act for the time being applies in relation to mor‐ phine or opium.
Every person who desires to obtain a licence under these regulations shall apply therefor to the Director-General on a form to be provided by the Ministry of Health, or, with the approval of the Medical Officer of Health, otherwise in writing.
The Director-General or the Medical Officer of Health may require any appli‐ cant for a licence to furnish information, by statutory declaration or otherwise, as to the nature of his or her business, the extent to which he or she proposes to deal in or otherwise utilise controlled drugs, and any other matter that appears to the Director-General or the Medical Officer of Health to be relevant.
Subject to section 14 of the Act and to subclauses (2) to (4) of regulation 7, the Director-General, if he or she is satisfied as to the propriety of the application, and, in the case of an applicant other than a government department or a corpo‐ rate body, as to the character of the applicant, and if he or she is also satisfied that the granting of a licence will not conflict with the international obligations of New Zealand, shall, upon the payment of the appropriate licence fee set out in Schedule 1AA, grant to the applicant a licence, for the purposes stated in the application, in terms required or permitted by these regulations and subject to such conditions, in addition to the conditions prescribed by or inserted in the licence pursuant to these regulations, as the Director-General sees fit to impose: provided that the Director-General may, at his or her discretion, remit the whole or part of such fee in any particular case or class of cases or in relation to any particular licence or class of licences.
Particulars of every licence shall be entered in a register kept for the purpose in the Ministry of Health.

Subject to these regulations, every licence shall be in such form as the Director-General may from time to time determine generally or in relation to any particular licence or class of licences.
Every licence shall be subject to the condition that the licensee will not contra‐ vene any provision of regulations 22 to 28, 31 to 33, 38, 40, 42, and 47, and will comply with every such provision so far as it is applicable.
(2) (3) (4) (5) (6) (7) 8 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 2 r 4 (8) For the purposes of section 14(6) of the Act and subclause (7) of this regula‐ tion, every contravention of or failure to comply with any provision of any regulation referred to in that subclause shall be a separate offence.

Regulation 3(1): replaced, on 11 October 2001, by regulation 4 of the Misuse of Drugs Amendment Regulations 2001 (SR 2001/231).
Regulation 3(1A): inserted, on 11 October 2001, by regulation 4 of the Misuse of Drugs Amendment Regulations 2001 (SR 2001/231).

Regulation 3(2): amended, on 1 July 1993, by regulation 3(1) of the Misuse of Drugs Regulations 1977, Amendment No 10 (SR 1993/157).

Regulation 3(4): amended, on 21 August 2006, by regulation 4 of the Misuse of Drugs (Fees) Amendment Regulations 2006 (SR 2006/189).
Regulation 3(5): amended, on 1 July 1993, by regulation 3(2) of the Misuse of Drugs Regulations 1977, Amendment No 10 (SR 1993/157).

3A Fees inclusive of GST The fees fixed by these regulations are inclusive of goods and services tax under the Goods and Services Tax Act 1985.

Regulation 3A: inserted, on 21 August 2006, by regulation 5 of the Misuse of Drugs (Fees) Amend‐ ment Regulations 2006 (SR 2006/189).
3B Application to industrial hemp (1) No licence under these regulations may be issued in respect of industrial hemp.

(2) Despite subclause (1), a licence may, in accordance with regulation 7, be issued to import or export industrial hemp.

Regulation 3B: inserted, as regulation 3A, on 1 August 2006, by regulation 5 of the Misuse of Drugs Amendment Regulations 2006 (SR 2006/164).
3C Application to medicinal cannabis products A licence to cultivate a prohibited plant, or to possess controlled drugs, must not be issued under these regulations in respect of any of the following, as defined by the Misuse of Drugs (Medicinal Cannabis) Regulations 2019: (a) (b) (c) any starting material: a cannabis-based ingredient: a medicinal cannabis product.

Regulation 3C: inserted, on 1 April 2020, by regulation 87 of the Misuse of Drugs (Medicinal Canna‐ bis) Regulations 2019 (LI 2019/321).
4 Dealers’ licences (1) Without prejudice to the generality of the expression “the propriety of the application” in regulation 3(4), the following matters shall be relevant to the propriety of any application for a dealer’s licence: (a) the necessity or expediency of the applicant holding a dealer’s licence for the purpose of carrying on his or her lawful affairs: 9 Part 2 r 4 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 (b) (c) (d) the situation and construction of the premises at which the applicant intends to deal in controlled drugs: the conditions under which the applicant intends to deal in controlled drugs: the kind or class of controlled drugs in which the applicant intends to deal and also, if he or she intends to manufacture controlled drugs, the amounts of the controlled drugs that he or she intends to manufacture.
(2) Every dealer’s licence— (a) (b) (c) (d) shall specify the kind or kinds of dealing authorised by the licence; and shall state that the licensee is authorised to deal in all controlled drugs, or, if that is not the case, shall specify, either by reference to a schedule of the Act or to a Part of any such schedule or by naming or otherwise identifying particular controlled drugs, the controlled drugs in which the licensee is authorised to deal; and shall specify, where the licence confers authority to manufacture con‐ trolled drugs, the amounts of the controlled drugs (other than exempted drugs) that the licensee is entitled to manufacture; and shall specify the full address of the premises at which the licensee may deal in controlled drugs.
(3) No dealer’s licence shall have the effect of authorising any manner of dealing in controlled drugs other than the manner specified or described in the licence, and no licence in which any controlled drug is specified shall have the effect of authorising the licensee to deal in any controlled drug not so specified.
(4) A separate dealer’s licence shall be necessary in respect of each different address at which the licensee intends to deal in controlled drugs, and no deal‐ er’s licence shall have the effect of authorising the licensee to deal in controlled drugs elsewhere than at the address specified in the licence.
(5) A dealer’s licence may not authorise— (a) (b) the supply of a controlled drug otherwise than pursuant to a prescription or order issued by a controlled drug prescriber; or the administration of a controlled drug otherwise than in accordance with the advice of the controlled drug prescriber who supplied or pre‐ scribed the controlled drug.

(6) Subclause (5) is subject to regulation 20.


Regulation 4(5): replaced, on 1 July 2014, by regulation 5 of the Misuse of Drugs Amendment Regu‐ lations 2014 (LI 2014/199).

Regulation 4(6): inserted, on 1 July 2014, by regulation 5 of the Misuse of Drugs Amendment Regu‐ lations 2014 (LI 2014/199).
10 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 2 r 6 5 (1) (2) (3) Endorsements on dealers’ licences Every holder of a dealer’s licence who wishes to deal in any controlled drug not specified in his or her licence, or to deal in any controlled drug in a manner not specified in his or her licence, shall apply in that behalf to the Director- General, and shall deliver his or her licence for endorsement.
Every holder of a dealer’s licence who wishes to deal in controlled drugs at any premises instead of the premises named in his or her licence shall apply in that behalf to the Director-General, specifying in his or her application the full address of the proposed substituted premises, and shall deliver his or her licence for endorsement.
If the Director-General approves an application under subclause (1) or sub‐ clause (2), he or she shall endorse the licence accordingly and enter particulars of the endorsement in the register referred to in regulation 3(5), and the licence thereafter shall have effect according to the tenor of the endorsement.

(4) No fee shall be payable in respect of an application under this regulation.
6 Duration and renewal of dealers’ licences (1) Unless sooner revoked under regulation 11, and subject to the succeeding pro‐ visions of this regulation, every dealer’s licence shall continue in force for a period of 1 year, and shall then expire.

(2) Any licence issued within the period of 2 months prior to the date of expiration of an existing licence that it is intended to supersede shall continue in force for a period of 1 year from that date.
(3) (4) If a licensee applies for a new licence not more than 3 months and not less than 1 month before the date of expiration of an existing licence that the new licence is intended to supersede, and the new licence is not granted before that date, the existing licence shall continue in force until the new licence is granted or refused.
Every holder of a dealer’s licence who desires to be licensed in the same terms after the expiration of a current licence shall apply in that behalf to the Director-General and pay the appropriate licence fee set out in Schedule 1AA at least 1 month before the expiration of his or her current licence, and it shall not be necessary to specify in the application the controlled drugs to which it is desired that the licence shall relate: provided that the Director-General may, at his or her discretion, remit the whole or part of the licence fee in any particular case or class of cases, or in relation to any particular licence or class of licences.
Regulation 6(4): amended, on 21 August 2006, by regulation 6 of the Misuse of Drugs (Fees) Amendment Regulations 2006 (SR 2006/189).
11 Part 2 r 7 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 7 Import and export licences (1) Without prejudice to the generality of the expression “the propriety of the application” in regulation 3(4), the purpose specified in any application for a licence to import or a licence to export controlled drugs as the purpose for which the controlled drugs are intended to be used after they have been impor‐ ted or exported shall be relevant to the propriety of the application.
(2) Except with the written approval of the Minister given in relation to a particu‐ lar case, no licence may be granted to import or export a controlled drug for the time being named in— (a) (b) (c) Schedule 1 of the Act: Part 1 of Schedule 2 of the Act: Part 1 of Schedule 3 of the Act.
(2A) However, the approval of the Minister under subclause (2) is not required for the grant of a licence to import or export— (a) cocaine, or in anything to which any of clauses 2 to 5 of Schedule 1 of the Act for the time being applies in relation to cocaine: (b) morphine or opium, or in anything to which any of clauses 2 to 5 of Part 1 of Schedule 2 of the Act for the time being applies in relation to mor‐ phine or opium.
(3) A licence to export controlled drugs shall be granted only on production of a certificate from the competent authority of the country to which the controlled drugs are to be exported to the effect that the importation into that country of the controlled drugs specified therein is approved.
(4) A licence to export controlled drugs for the purpose of placing them in a bon‐ ded warehouse shall be granted only if the Government of the importing coun‐ try certifies on the certificate referred to in subclause (3) that it has approved the importation for the purpose of being placed in a bonded warehouse.
Every licence to import and every licence to export controlled drugs shall spe‐ cify the name or description of the controlled drug that is the subject of the licence, the quantity of the controlled drug permitted to be imported or expor‐ ted, the name and address of the importer or exporter, the period within which the importation or exportation must be effected, and the address (not being a post office or a telegraphic or code address) to which the controlled drugs are to be consigned.
Every licence to export controlled drugs shall identify the import certificate referred to in subclause (3) by reference to the number and date of the certifi‐ cate and the authority by whom it was issued and, in every case where the con‐ trolled drugs are being exported for the purpose of being placed in a bonded warehouse, the licence shall specify that the controlled drugs are being expor‐ ted for that purpose.
(5) (6) 12 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 2 r 8 (7) (8) Every licence to export controlled drugs shall be subject to the condition that a copy of the licence will accompany each consignment of the controlled drugs to which the licence relates.

Every licence to import and every licence to export controlled drugs shall cease to have effect on the expiration of the period stated therein as the period within which importation or exportation must be effected.
(9) A licence to import, or a licence to export, controlled drugs must not be granted in respect of any starting material, cannabis-based ingredient, or medicinal can‐ nabis product (all as defined by the Misuse of Drugs (Medicinal Cannabis) Regulations 2019) unless— (a) (b) the applicant holds a medicinal cannabis licence (as defined by those regulations); or the applicant is a medical practitioner whose purpose is to import the controlled drugs to prescribe, supply, or administer them for the treat‐ ment of particular patients under their care, and the Minister gives writ‐ ten approval to the grant of the licence; or (c) the applicant is a pharmacist whose purpose is to import the controlled drugs for a prescription to which paragraph (b) applies.
Regulation 7(2): replaced, on 11 October 2001, by regulation 6 of the Misuse of Drugs Amendment Regulations 2001 (SR 2001/231).

Regulation 7(2A): inserted, on 11 October 2001, by regulation 6 of the Misuse of Drugs Amendment Regulations 2001 (SR 2001/231).

Regulation 7(9): inserted, on 1 April 2020, by regulation 88 of the Misuse of Drugs (Medicinal Can‐ nabis) Regulations 2019 (LI 2019/321).
8 (1) Licences to cultivate Every licence to cultivate a prohibited plant shall specify the prohibited plant that the licensee may cultivate, and, without prejudice to the power of the Director-General to impose conditions to which the licence is subject, shall describe the land or specify the full address of the premises on which such cul‐ tivation is authorised and specify either the area of that land or the number of plants that may be cultivated thereon or at such premises at any one time.
(2) No licence to cultivate a prohibited plant shall authorise the cultivation— (a) (b) of any plant of the species Lophophora williamsii or Lophophora lewinii for the purpose of the production of mescaline: of any plant of the species Psilocybe mexicana or Psilocybe cubensis for the purpose of the production of psilocine or psilocybine.
(3) A licence to cultivate a prohibited plant shall cease to have effect on the expir‐ ation of the period, if any, specified therein in that behalf, but any such licence may be granted for an indefinite period.
13 Part 2 r 9 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 9 (1) Licences to possess controlled drugs Subject to section 14 of the Act, a licence to possess controlled drugs may be granted— (a) to any person, specified by name or office, in charge of or employed at a field research station, or in charge of or employed in a laboratory main‐ tained for the purpose of research and study at a university or other insti‐ tution; or (b) to any other person if the Director-General is of the opinion that— (i) that person may not be entitled by or under any other provision of these regulations to possess controlled drugs for the purpose for which that person requires controlled drugs; and (ii) that purpose is a proper purpose.
(2) A licence to possess controlled drugs— (a) (b) (c) shall specify the paragraph of subclause (1) under which it is granted: shall specify the purpose for which it is granted: shall specify the controlled drugs to which it applies: (d) may specify the quantities of controlled drugs that may be in the posses‐ sion of the licensee at any one time.
(3) A licence to possess controlled drugs shall not have the effect of authorising the possession of controlled drugs of a kind other, or in greater quantity than, the kind or quantity (if any) specified in the licence, or the kind or quantity required for the purpose of the field research station or laboratory or other pur‐ pose specified in the licence.
(4) A licence to possess controlled drugs shall cease to have effect on the expir‐ ation of the period (if any) specified therein in that behalf, but any such licence may be granted for an indefinite period.

10 Licences not to be assigned (1) No licence, and no right thereby conferred, shall be exercised by any person other than the licensee, or be assigned, charged, or alienated to or in favour of, or be capable of devolving upon, any person, whether by act of the parties or by operation of law.
(2) Notwithstanding anything in subclause (1), where a licence is granted to an officer of a government department or other instrument of the Crown, or to a person pursuant to regulation 9(1)(a), in the name of his or her office, any per‐ son holding or acting in that office for the time being, but no other person, shall be the licensee.
Revocation of licences The Minister may at any time, by notice in the Gazette, revoke a licence— 11 (1) 14 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 3 r 12A (a) (b) (c) if the licensee is convicted of an offence against the Act or these regula‐ tions; or if the Minister is satisfied that the licensee has contravened or failed to comply with any condition contained in the licence whether imposed by these regulations or by the terms of that licence; or if it appears to the Minister that the licence has been granted in error or through any misrepresentation or fraud, or has been granted without his or her approval to a person to whom, or in respect of a controlled drug in relation to which, the licence should not have been granted without the approval of the Minister.
Every person whose licence is revoked shall deliver his or her licence to the Director-General within 1 month after that revocation.

Every person who fails to comply with subclause (2) commits an offence against these regulations.

Part 3 Permissions Effect of this Part The several permissions conferred by this Part may be exercised without any licence in that behalf, but nothing herein contained shall prevent the grant of a licence to any person.

This Part shall be read subject to Parts 4, 5, and 6.
Every person, other than a licensee, who contravenes any provision of regula‐ tions 21 to 26, 28, 29, 31 to 33, 35, 37, 38, 40, 42 to 45, or 47, or fails to com‐ ply with any such provision to the extent that it is applicable, commits an offence against these regulations.
(2) (3) 12 (1) (2) (3) 12A Authority for designated prescriber nurses, designated prescriber pharmacists, midwives, and nurse practitioners to prescribe certain controlled drugs (1) For the purposes of section 8(1)(m) of the Act,— (a) (b) (c) a designated prescriber nurse is authorised by this regulation to prescribe a controlled drug specified in Schedule 1A: a designated prescriber pharmacist is authorised by this regulation to prescribe a controlled drug specified in Schedule 1B: a midwife is authorised by this regulation to prescribe a controlled drug specified in Schedule 1C: (d) a nurse practitioner is authorised by this regulation to prescribe any— (i) Class A controlled drug: 15 Part 3 r 12B Misuse of Drugs Regulations 1977 Version as at 5 October 2023 (ii) Class B controlled drug: (iii) Class C controlled drug.
(2) The authorities given in subclause (1) are subject to— (a) (b) sections 22 to 25 of the Act; and any prohibitions, limitations, restrictions, or conditions imposed by or under those sections or by regulations made under the Act.

Regulation 12A: replaced, on 1 July 2014, by regulation 6 of the Misuse of Drugs Amendment Regu‐ lations 2014 (LI 2014/199).

Regulation 12A(1): amended, on 31 January 2018, by section 8(2) of the Misuse of Drugs Amend‐ ment Act 2016 (2016 No 80).
12B Permissions relating to prescription of controlled drugs authorised under regulation 12A (1) This section applies to any person (a patient) for whom a controlled drug is— (a) (b) supplied by a prescriber; or prescribed by a prescriber and lawfully supplied.

(2) The controlled drug may be administered to the patient by— (a) (b) the patient himself or herself in accordance with the advice of the pre‐ scriber; or a person who has the care of the patient in accordance with the advice of the prescriber.
(3) Subclauses (1) and (2) contain permissions that— (a) are exceptions to the prohibitions in sections 6(1) and 7(1) of the Act; and (b) are subject to— (i) (ii) sections 22 to 25 of the Act; and any prohibitions, limitations, restrictions, or conditions imposed by or under those sections or by regulations made under the Act.
(4) In this section, prescriber means any of the following authorised prescribers who prescribes a controlled drug in accordance with an authority given under regulation 12A: (a) (b) (c) (d) a designated prescriber nurse: a designated prescriber pharmacist: a midwife: a nurse practitioner.

Regulation 12B: replaced, on 1 July 2014, by regulation 6 of the Misuse of Drugs Amendment Regu‐ lations 2014 (LI 2014/199).
16 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 3 r 15 12C Authority for designated pharmacist prescribers to prescribe certain controlled drugs [Revoked] Regulation 12C: revoked, on 1 July 2014, by regulation 6 of the Misuse of Drugs Amendment Regu‐ lations 2014 (LI 2014/199).

13 Manufacture and use in manufacture (1) Any person may use an exempted drug in the manufacture of another exempted drug, or of a product that is not a controlled drug.
(2) Any medical practitioner or dentist may use any controlled drug in the manu‐ facture of any other controlled drug required for the treatment of a patient under his or her care.

(3) Any veterinarian within the meaning of section 4 of the Veterinarians Act 2005 may use any controlled drug in the manufacture of any other controlled drug required for the treatment of an animal under his or her care.
(4) Any pharmacist may use any controlled drug in the manufacture of any other controlled drug that he or she is authorised to produce or manufacture by sec‐ tion 8(1)(b) of the Act.

(5) Nothing in subclauses (2) to (4) shall apply to any practitioner or pharmacist who is for the time being prohibited under section 23 of the Act from prescrib‐ ing, producing, manufacturing, or supplying controlled drugs.
Regulation 13(3): amended, on 22 December 2005, pursuant to section 95 of the Veterinarians Act 2005 (2005 No 126).

Regulation 13(4): amended, on 22 December 2022, by regulation 4 of the Misuse of Drugs Amend‐ ment Regulations 2022 (SL 2022/303).
14 General authority of licensees to possess (1) Any person who is licensed under these regulations to import or export a con‐ trolled drug or to deal in a controlled drug may possess that drug in the manner and for the purpose expressed or implied in the licence.

(2) Any person who is licensed under these regulations to cultivate a prohibited plant may possess the seed and fruit of that plant in the manner and for the pur‐ pose expressed or implied in that licence.
14A Authority to import CBD products [Revoked] Regulation 14A: revoked, on 18 December 2018, by section 12(3) of the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 (2018 No 54).
15 Hospitals and other institutions Without prejudice to any provision of section 8(1) of the Act, every manager of a hospital, and every manager of an institution for the care of the sick or aged that is for the time being approved by the Director-General for the purposes of 17 Part 3 r 16 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 this regulation, may possess any controlled drug named or described in Part 2 of Schedule 3 of the Act and any partially exempted drug.
Regulation 15 heading: amended, on 1 July 1993, by regulation 4 of the Misuse of Drugs Regulations 1977, Amendment No 10 (SR 1993/157).

Regulation 15: amended, on 22 December 2022, by regulation 5 of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 15: amended, on 15 October 2004, by regulation 4(1) of the Misuse of Drugs (Ephedrine and Pseudoephedrine) Amendment Regulations 2004 (SR 2004/315).
Regulation 15: amended, on 15 October 2004, by regulation 4(2) of the Misuse of Drugs (Ephedrine and Pseudoephedrine) Amendment Regulations 2004 (SR 2004/315).

Regulation 15: amended, on 1 July 1993, by regulation 4 of the Misuse of Drugs Regulations 1977, Amendment No 10 (SR 1993/157).

16 (1) Seeds and fruit of prohibited plants This regulation applies to seeds and fruit, not being controlled drugs, of pro‐ hibited plants.
(2) Any person in the service of the Crown may possess any seed or fruit to which this regulation for the time being applies for the purposes of and in connection with his or her official duties.

(3) Any carrier, and any agent or servant of a carrier, may possess any seed or fruit to which this regulation for the time being applies in the course of carriage to such extent as is necessary or incidental to the business of the carrier.
17 (1) Special authority for masters of vessels The master of any vessel for the time being within the territorial limits of New Zealand, and any person acting under his or her directions and on his or her behalf, may possess, import, export, and administer any controlled drug author‐ ised or required to be carried on that vessel by any law to which that vessel is subject, and lawfully supplied to him or her.
(2) Nothing in subclause (1) shall authorise the master of any vessel or any other person— (a) to possess controlled drugs elsewhere than on the vessel of which the first-mentioned person is the master, except while the controlled drugs are being conveyed from the place where they were procured by either of those persons to that vessel; or (b) to import, export, administer, or otherwise use controlled drugs except for the purpose of treating sick or injured persons on that vessel.
Special authority for captains of aircraft The person in charge of any aircraft for the time being within the territorial limits of New Zealand, and any person acting under his or her directions and on his or her behalf, may possess, import, export, and, in any case where the administration of a controlled drug is expedient for the purpose of treating a sick or injured person in an emergency, administer to that person any controlled 18 (1) 18 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 3 r 19 drug authorised or required to be carried on the aircraft by any law to which that aircraft is subject, and lawfully supplied to him or her.
(2) Nothing in subclause (1) shall authorise the person for the time being in charge of any aircraft or any other person— (a) to possess controlled drugs elsewhere than on the aircraft of which the first-mentioned person is for the time being in charge, except while the controlled drugs are being conveyed from the place where they were procured by either of those persons to that aircraft or while the aircraft is being surveyed, examined, or overhauled; or (b) to import, export, administer, or otherwise use controlled drugs except for the purpose of treating sick or injured persons in an emergency.
19 (1) First-aid kits In this regulation the expression approved first-aid kit means a first-aid kit that is held for ready use in the event of emergency in a place, locality, vessel, or vehicle approved in writing by the Medical Officer of Health, and that is— (a) (b) (c) (d) under the control of a person in an isolated locality where workers are employed; or under the control of a nurse appointed as an occupational health nurse in any place where a first-aid post or similar post is established for the benefit of workers employed there; or under the control of a person representing an organisation established for search and rescue in mountainous or isolated areas; or under the control of a person belonging to a class approved by the Director-General or under the control of any person in a place, locality, vessel, or vehicle so approved.
(2) Any approval for the purposes of subclause (1) shall be deemed to be given upon and subject to such terms and conditions as may be specified therein, and may at any time be revoked by the Director-General, whether or not the appro‐ val was given by him or her.
(3) Subject to the provisions of this regulation and to any conditions that may from time to time be imposed by the Medical Officer of Health in any particular case, any person for the time being having control of an approved first-aid kit may possess and administer to any person any controlled drug lawfully con‐ tained in that kit.
(4) Nothing in subclause (3) shall authorise any person to administer controlled drugs except for the purpose of treating a sick or injured person in an emer‐ gency arising in the locality, vessel, or vehicle for which the controlled drugs were supplied.
19 Part 3 r 20 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 (5) (6) The permission conferred by subclause (3) shall extend to any person nomin‐ ated in writing in that behalf by the person having the approved first-aid kit under his or her control.
Every person in possession of controlled drugs by virtue of subclause (3) who, except as may be permitted by the Medical Officer of Health, keeps those con‐ trolled drugs, or causes or permits them to be kept, elsewhere than in an approved first-aid kit under his or her control or under the control of a person nominated in that behalf pursuant to subclause (5), or who contravenes or fails to comply with any condition imposed by the Medical Officer of Health under subclause (3), commits an offence against these regulations.
(7) Every nomination under subclause (5), and any controlled drug possessed by virtue of this regulation, shall be available at any time for inspection by any constable or any officer.
(8) Any person having control of an approved first-aid kit, and wishing to obtain controlled drugs for the purposes of that kit, shall apply in writing to the Med‐ ical Officer of Health in that behalf, specifying— (a) (b) (c) the name and quantity of the controlled drugs required: in the case of a first-aid kit in a place where workers are employed, the number of workers to be served: details of the locality where the work is to be performed, or of the area in which the first-aid kit is likely to be used, and the period for which the supply is required: (d) such other particulars as the Medical Officer of Health may require.
Regulation 19(1)(b): amended, on 18 September 2004, by section 175(3) of the Health Practitioners Competence Assurance Act 2003 (2003 No 48).

Regulation 19(7): amended, on 1 October 2008, pursuant to section 116(a)(ii) of the Policing Act 2008 (2008 No 72).
20 Supply and administration of controlled drugs without prescription (1) Despite section 8(1)(b) of the Act or regulation 4(5), a controlled drug may be supplied, otherwise than pursuant to a prescription, to or for— (a) (b) (c) (d) (e) a person licensed or otherwise authorised to export, use in manufacture, or supply that drug: a person to whom the drug is supplied in an emergency in accordance with regulation 34: a person authorised to possess that drug by section 8(1)(g) or (i) of the Act: a person licensed to possess the drug or authorised to possess the drug by any of regulations 15, 17, and 18: a person authorised to possess the drug by regulation 19 if the person supplying the drug has been authorised in writing by the Medical Officer 20 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 4 r 21 of Health to supply the drug, on the particular occasion, to the person procuring it.
(2) Without prejudice to any provision of section 8 of the Act— (a) (b) any person may supply, otherwise than pursuant to a prescription, or administer, any partially exempted drug, subject to subclause (3): any person may administer, subject to and in accordance with regulation 36(2), a controlled drug to a maternity patient.
(3) For the purposes of subclause (2)(a), the following restrictions apply to the supply of any preparation of pseudoephedrine described in paragraph (b) of the definition of partially exempted drug: (a) the preparation may be sold by retail, or supplied in circumstances cor‐ responding to retail sale, only in the circumstances set out in paragraphs (a) and (b) of the definition of pharmacy-only medicine in section 3 of the Medicines Act 1981; and (b) the package in which the preparation is sold or supplied must not contain more than 1.8 g of pseudoephedrine.
Regulation 20(1): amended, on 22 December 2022, by regulation 6(1) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 20(1)(c): amended, on 22 December 2022, by regulation 6(2) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 20(2)(a): amended, on 15 October 2004, by regulation 5(1) of the Misuse of Drugs (Ephe‐ drine and Pseudoephedrine) Amendment Regulations 2004 (SR 2004/315).
Regulation 20(3): inserted, on 15 October 2004, by regulation 5(2) of the Misuse of Drugs (Ephe‐ drine and Pseudoephedrine) Amendment Regulations 2004 (SR 2004/315).
Part 4 Restrictions and conditions 21 Restrictions on application of section 8 of Act, etc (1) Nothing in section 8 of the Act or in these regulations, or in any licence granted under these regulations, shall authorise any dealing in a controlled drug con‐ trary to any provision of these regulations or of section 20 or section 24 of the Medicines Act 1981.
(2) No medical practitioner may issue a prescription for the supply of a controlled drug otherwise than for the medical treatment of a patient under his or her care, unless the medical practitioner is acting in the course of his or her employment in the service of the Crown.
(3) No dentist may issue a prescription for the supply of a controlled drug— (a) (b) otherwise than for the treatment of a patient under the dentist’s care; and in any quantity greater than the quantity reasonably required for the treatment of the patient for a period of 7 days.
21 Part 4 r 21 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 (4) No designated prescriber nurse may (within the authority given by regulation 12A(1)(a)) issue a prescription for the supply of a controlled drug— (a) (b) (c) otherwise than for the treatment of a patient under the designated pre‐ scriber nurse’s care; and [Revoked] in any quantity greater than the quantity reasonably required for the treatment of the patient for a period of 7 days.
(4A) [Revoked] (4B) [Revoked] (4C) [Revoked] (5) No designated prescriber pharmacist may (within the authority given by regula‐ tion 12A(1)(b)) issue a prescription for the supply of a controlled drug— (a) (b) otherwise than for the treatment of a patient under the designated pre‐ scriber pharmacist’s care; and in any quantity greater than the quantity reasonably required for the treatment of the patient for a period of 3 days.
(5A) No midwife may (within the authority given by regulation 12A(1)(c)) issue a prescription for the supply of a controlled drug otherwise than for the treatment of a patient under the midwife’s care.
(5B) No nurse practitioner may (within the authority given by regulation 12A(1)(d)) issue a prescription for the supply of a controlled drug— (a) (b) otherwise than for the treatment of a patient under the nurse practition‐ er’s care; and in the case of a Class A controlled drug, in any quantity greater than the quantity reasonably required for the treatment of the patient for a period of 1 month.
(5C) No veterinarian may issue a prescription for the supply of a controlled drug otherwise than for administration to an animal under the veterinarian’s care.
(5D) Despite subclauses (3), (4), (5), and (5B), within the authority conferred by regulation 12A(1) a medical practitioner, nurse practitioner, designated pre‐ scriber nurse, designated prescriber pharmacist, midwife, or dentist may issue— (a) (b) a prescription for the supply of an opioid Class A, Class B, or Class C controlled drug in any quantity not greater than the quantity reasonably required for the treatment of the patient for 1 month: a prescription for the supply of a non-opioid Class B or Class C con‐ trolled drug in any quantity not greater than the quantity reasonably required for the treatment of the patient for 3 months.
22 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 4 r 21 (5E) Despite subclause (5D)(a), a specified medical practitioner, or a prescriber authorised by a specified medical practitioner or by a medical practitioner authorised by a specified medical practitioner, may issue a prescription for the supply of any opioid Class A, Class B, or Class C controlled drug in any quan‐ tity not greater than the quantity reasonably required for the treatment of the patient for 3 months for the purposes of section 24A of the Act.
(6) Section 8(1)(c) of the Act does not apply where the person for whose benefit the controlled drug is supplied or prescribed is in the course of being supplied with the same controlled drug for the same purpose by another practitioner, or pursuant to a prescription issued by another practitioner, and does not disclose that fact to the practitioner referred to in that paragraph before the supply of the controlled drug, or the issuing of the prescription, by that practitioner.
Regulation 21(1): amended, on 1 July 1993, by regulation 5 of the Misuse of Drugs Regulations 1977, Amendment No 10 (SR 1993/157).

Regulation 21(2): amended, on 22 December 2022, by regulation 7(1) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 21(3): replaced, on 1 July 2014, by regulation 7 of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).
Regulation 21(3): amended, on 22 December 2022, by regulation 7(2) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 21(4): replaced, on 1 July 2014, by regulation 7 of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).

Regulation 21(4): amended, on 22 December 2022, by regulation 7(2) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
Regulation 21(4)(b): revoked, on 20 September 2016, by regulation 5(1) of the Misuse of Drugs Amendment Regulations 2016 (LI 2016/139).

Regulation 21(4)(c): amended, on 20 September 2016, by regulation 5(2) of the Misuse of Drugs Amendment Regulations 2016 (LI 2016/139).

Regulation 21(4A): revoked, on 1 July 2014, by regulation 7 of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).
Regulation 21(4B): revoked, on 1 July 2014, by regulation 7 of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).

Regulation 21(4C): revoked, on 1 July 2014, by regulation 7 of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).

Regulation 21(5): replaced, on 1 July 2014, by regulation 7 of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).

Regulation 21(5): amended, on 22 December 2022, by regulation 7(2) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
Regulation 21(5A): inserted, on 1 July 2014, by regulation 7 of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).

Regulation 21(5A): amended, on 22 December 2022, by regulation 7(2) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 21(5B): inserted, on 1 July 2014, by regulation 7 of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).
Regulation 21(5B): amended, on 22 December 2022, by regulation 7(2) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

23 Part 4 r 22 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 Regulation 21(5B)(b): replaced, on 5 October 2023, by regulation 4(1) of the Misuse of Drugs Amendment Regulations (No 2) 2023 (SL 2023/231).

Regulation 21(5C): inserted, on 1 July 2014, by regulation 7 of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).
Regulation 21(5C): amended, on 22 December 2022, by regulation 7(2) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 21(5D): replaced, on 5 October 2023, by regulation 4(2) of the Misuse of Drugs Amend‐ ment Regulations (No 2) 2023 (SL 2023/231).

Regulation 21(5E): inserted, on 5 October 2023, by regulation 4(2) of the Misuse of Drugs Amend‐ ment Regulations (No 2) 2023 (SL 2023/231).
Regulation 21(6): amended, on 22 December 2022, by regulation 7(4)(a) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 21(6): amended, on 22 December 2022, by regulation 7(4)(b) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 21(6): amended, on 22 December 2022, by regulation 7(4)(c) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
22 (1) Restriction on supply of certain controlled drugs Except to the extent and in the circumstances approved by the Minister either generally or in relation to any particular case or class of cases, no person may supply or administer to any other person, or may prescribe, any controlled drug for the time being named or described in— (a) (b) (c) Schedule 1 of the Act: Part 1 or Part 2 of Schedule 2 of the Act: Part 1 of Schedule 3 of the Act.
(2) However, the approval of the Minister under subclause (1) is not required for the supply, administration, or prescribing of— (a) cocaine, or anything to which any of clauses 2 to 5 of Schedule 1 of the Act for the time being applies in relation to cocaine: (b) morphine or opium, or anything to which any of clauses 2 to 5 of Part 1 of Schedule 2 of the Act for the time being applies in relation to mor‐ phine or opium: (c) any of the following that have been assessed as complying with the min‐ imum quality standard, and specified in a medicinal cannabis licence accordingly, under the Misuse of Drugs (Medicinal Cannabis) Regula‐ tions 2019: (i) (ii) a consignment of starting material for export: a cannabis-based ingredient: (iii) a medicinal cannabis product: (c) (d) [Revoked] fentanyl.
24 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 4 r 23 Regulation 22: replaced, on 11 October 2001, by regulation 9 of the Misuse of Drugs Amendment Regulations 2001 (SR 2001/231).

Regulation 22(2)(c): inserted, on 1 April 2020, by regulation 89 of the Misuse of Drugs (Medicinal Cannabis) Regulations 2019 (LI 2019/321).

Regulation 22(2)(c): revoked, on 18 December 2018, by section 12(4) of the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 (2018 No 54).
Regulation 22(2)(d): inserted, on 15 December 2022, by regulation 4 of the Misuse of Drugs (Fen‐ tanyl and Tramadol) Amendment Regulations 2022 (SL 2022/36).
23 Conditions of supply to agents (1) No person other than a practitioner shall supply any Class A controlled drug or Class B controlled drug, not being a controlled drug supplied pursuant to a pre‐ scription, to any other person, unless the person supplying the controlled drug holds a written authority— (a) (b) (c) setting out the name and address of the person for whom the controlled drug is to be supplied; and specifying by name and quantity the controlled drug to be supplied; and specifying or describing the intended method of delivery to the person for whom the controlled drug is to be supplied; and (d) signed by the person for whom the controlled drug is to be supplied: provided that in cases of emergency a controlled drug may be supplied without the written authority, but in that event the person to whom the controlled drug is supplied shall give the supplier the written authority within 48 hours after delivery, and, if the supplier fails to receive the authority within that period, he or she shall report the circumstances forthwith in writing to the Medical Officer of Health.
(2) Every person supplying a controlled drug pursuant to subclause (1) shall— (a) (b) (c) (d) before supplying the controlled drug (except where it is supplied pur‐ suant to the proviso to that subclause) satisfy himself or herself that the authority referred to in that subclause has been duly completed, and, in particular, that it has been signed by the person for whom the controlled drug is to be supplied; and endorse on the face of that authority at the time of supply or at the time when he or she receives the authority, as the case may require, above the signature of the person for whom the controlled drug is to be supplied, the name and address of the premises from which, and the date on which, the controlled drug is or was supplied; and sign that endorsement; and retain that authority or cause that authority to be retained, in an orderly and consecutive manner in relation to other such authorities, at the prem‐ ises from which the controlled drug was supplied for a period of 4 years from the date on which that controlled drug was supplied; and 25 Part 4 r 24 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 (e) permit any constable and any officer to examine that authority and make copies thereof.
(3) No person shall supply any controlled drug for delivery through the post except for delivery by registered or insured post.

(4) This regulation shall not apply in respect of any exempted drug.

Regulation 23(1): amended, on 3 January 1980, by regulation 2 of the Misuse of Drugs Regulations 1977, Amendment No 3 (SR 1979/274).

Regulation 23(2)(e): amended, on 1 October 2008, pursuant to section 116(a)(ii) of the Policing Act 2008 (2008 No 72).
Regulation 23(3): amended, on 19 May 1978, by regulation 2(2) of the Misuse of Drugs Regulations 1977, Amendment No 2 (SR 1978/142).

Regulation 23(4): inserted, on 19 May 1978, by regulation 2(1) of the Misuse of Drugs Regulations 1977, Amendment No 2 (SR 1978/142).

24 (1) Supply on prescription Subject to regulation 30, no person shall supply a controlled drug pursuant to a prescription that does not conform in all respects with regulation 29.
(2) No person shall supply a controlled drug pursuant to a prescription otherwise than by delivery, by himself or herself or by a person in his or her employment, to the person for whom the drug is intended or at the premises where that per‐ son resides, or by delivery by registered post, or by delivery through a carrier, unless— (a) (b) the person to whom he or she makes delivery gives to him or her a writ‐ ten authority in the terms that would have been required by regulation 23(1) if the controlled drug had not been dispensed pursuant to a pre‐ scription; or he is otherwise satisfied that the person to whom he or she makes deliv‐ ery has the care of the person for whom the controlled drug is intended or is authorised by the last-mentioned person to accept delivery of the controlled drug.
Labelling of containers Except in the case of a container to which subclause (3) applies, no person shall supply any controlled drug (other than an exempted drug) unless the con‐ tainer containing the controlled drug bears a label setting out, in letters of a col‐ our contrasting clearly with the colour of the background, the following: (a) (b) (c) in the upper part of the principal display panel, printed in conspicuous block capital letters, the words “CONTROLLED DRUG”, followed immediately by the appropriate designation specified in subclause (2); and the name of the controlled drug supplied; and directions for use, or, in the case of a drug for internal use, the recom‐ mended dose and frequency of the dose; and 25 (1) 26 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 4 r 25 (d) where the controlled drug is in the form of a preparation, mixture, or art‐ icle, the name (if any) of the preparation, mixture, or article, together with a statement of the proportion that the controlled drug bears to the total ingredients of the preparation, mixture, or article, indicating (if the proportion is stated as a percentage) whether the percentage is calculated on the basis of weight in weight, or weight in volume, or volume in vol‐ ume; and (e) the name and address of the manufacturer, or the packer, or the seller by wholesale or by retail.
(2) For the purposes of subclause (1), the appropriate designation, in relation to a controlled drug, is as follows: “(A)” “(B1)” “(B2)” “(B3)” “(C1)” “(C2)” “(C3)” “(C4)” “(C5)” to indicate a controlled drug for the time being named or described in Schedule 1 of the Act: to indicate a controlled drug for the time being named or described in Part 1 of Schedule 2 of the Act: to indicate a controlled drug for the time being named or described in Part 2 of Schedule 2 of the Act: to indicate a controlled drug for the time being named or described in Part 3 of Schedule 2 of the Act: to indicate a controlled drug for the time being named or described in Part 1 of Schedule 3 of the Act: to indicate a controlled drug for the time being named or described in Part 2 of Schedule 3 of the Act: to indicate a controlled drug for the time being named or described in Part 3 of Schedule 3 of the Act: to indicate a controlled drug for the time being named or described in Part 4 of Schedule 3 of the Act: to indicate a controlled drug for the time being named or described in Part 5 of Schedule 3 of the Act.
(3) Subclause (1) does not apply,— (a) in respect of ephedrine or pseudoephedrine, if— (i) (ii) the drug is enclosed in a primary container that complies with regulation 15(2) of the Medicines Regulations 1984; and the larger container in which the strips of primary containers are contained complies with subclause (1); and (b) in respect of all other controlled drugs, if— (i) (ii) the drug is contained in a safety container within the meaning of regulation 2(1) of the Medicines Regulations 1984; and the labelling of the safety container complies with the Medicines Regulations 1984.
27 Part 4 r 25 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 (3A) Subclause (1) does not apply in respect of any controlled drug supplied pur‐ suant to a prescription issued by a controlled drug prescriber.
(4) No person shall, in the course of any profession or business, supply any con‐ trolled drug (other than an exempted drug) as a medicine for human use, with reference to the needs of a particular patient, unless the container of the con‐ trolled drug bears a label setting out the following: (a) either— (i) the general nature of the medicine, and a recognised code that indicates the precise nature of the contents or consists of a refer‐ ence to a prescription book or similar record; or (ii) the name or a description of the nature of the contents; and (b) either— (i) (ii) in the case of a medicine for internal use, the dose and frequency of the dose; or in the case of a medicine for external use, the directions for use; and (c) (d) the name of the patient; and the name and address of the supplier.
(5) No person shall, in the course of any profession or business, supply any con‐ trolled drug (other than an exempted drug) as a remedy for the treatment of an animal, unless the container of the controlled drug bears a label setting out the following: (a) either— (i) the general nature of the remedy, and a recognised code that indi‐ cates the precise nature of the contents or consists of a reference to a prescription book or similar record; or (ii) the name or a description of the nature of the contents; and (b) (c) (d) the directions for use; and the name of the person in charge of the animal; and the words “Not for Human Use” or the words “For Veterinary Use Only”.
(6) In any proceedings in respect of an alleged contravention of subclause (1) in which regulation 25A is pleaded in defence, the burden of proving that defence lies on the person charged.

(7) [Revoked] Regulation 25(3): replaced, on 15 October 2004, by regulation 6(1) of the Misuse of Drugs (Ephe‐ drine and Pseudoephedrine) Amendment Regulations 2004 (SR 2004/315).

Regulation 25(3)(a)(i): amended, on 1 August 2011, by regulation 30(2) of the Medicines Amend‐ ment Regulations 2011 (SR 2011/245).
28 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 4 r 26 Regulation 25(3)(b)(ii): replaced, on 1 August 2011, by regulation 30(3) of the Medicines Amend‐ ment Regulations 2011 (SR 2011/245).

Regulation 25(3A): replaced, on 1 July 2014, by regulation 8 of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).

Regulation 25(3A): amended, on 22 December 2022, by regulation 8 of the Misuse of Drugs Amend‐ ment Regulations 2022 (SL 2022/303).
Regulation 25(6): replaced, on 16 June 2023, by regulation 5 of the Misuse of Drugs Amendment Regulations 2023 (SL 2023/129).

Regulation 25(7): revoked, on 16 June 2023, by regulation 5 of the Misuse of Drugs Amendment Regulations 2023 (SL 2023/129).
25A Exemptions from regulation 25 (1) The requirement in regulation 25(1) for a label to display the appropriate desig‐ nation does not apply in respect of a controlled drug supplied by a manufac‐ turer or wholesaler,— (a) (b) if the appropriate designation of the controlled drug described in regula‐ tion 25(2) has changed, for the period of 6 months immediately follow‐ ing the date on which the designation changed; and if the designation as a controlled drug is new, for the period of 6 months immediately following the date on which the substance was added to Schedule 1, 2, or 3 of the Act.
(2) The requirement in regulation 25(1) for a label to display the appropriate desig‐ nation does not apply in respect of a controlled drug supplied by a retailer,— (a) (b) if the appropriate designation of the controlled drug described in regula‐ tion 25(2) has changed, for the period of 9 months immediately follow‐ ing the date on which the designation changed; and if the designation as a controlled drug is new, for the period of 9 months immediately following the date on which the substance was added to Schedule 1, 2, or 3 of the Act.
Regulation 25A: inserted, on 16 June 2023, by regulation 6 of the Misuse of Drugs Amendment Regulations 2023 (SL 2023/129).
26 (1) (2) Restrictions on sizes of containers [Revoked] Subject to subclause (3), no person shall supply to a pharmacy a controlled drug of any type or kind specified in any of paragraphs (a) to (e) in a container that contains a quantity of that drug in excess of the amount so specified: (a) powders: cocaine hydrochloride: methadone hydrochloride: morphine hydrochloride: morphine sulphate: 29 Part 4 r 27 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 an amount per container not exceeding 2 grams: (b) liquid dose form of methadone or morphine: an amount per container not exceeding 100 millilitres or, where the total amount of morphine or methadone in a container does not exceed 2 grams, an amount per container not exceeding 200 millilitres: (c) liquid dose form of nepenthe or opium tincture: an amount per container not exceeding 100 millilitres: (d) solid dose form: dextromoramide: levorphanol: methadone: morphine sulphate: papaveretum: pethidine: an amount per container not exceeding 10 items in solid dose form: (e) ampoules (whether or not the controlled drug is mixed with any other substance): dextromoramide: levorphanol: methadone: morphine: papaveretum: pethidine: an amount per container not exceeding 5 ampoules.
(3) Subclause (2) shall not apply to a controlled drug packed for supply in its ori‐ ginal container to a hospital or other institution.

Regulation 26: replaced, on 9 May 1995, by regulation 2(1) of the Misuse of Drugs Regulations 1977, Amendment No 11 (SR 1995/75).

Regulation 26(1): revoked, on 18 September 2004, by section 175(3) of the Health Practitioners Competence Assurance Act 2003 (2003 No 48).
27 Controlled drugs used for exempted drugs (1) No person who is licensed to deal in any controlled drug for the purpose of manufacturing an exempted drug shall use any such controlled drug in any such manufacture in contravention of a direction given under subclause (2).
30 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 4 r 28 (2) The Director-General may, by notice in writing, served either personally or by registered post on a person licensed as aforesaid, direct that person not to use any such controlled drug in the manufacture of an exempted drug unless— 28 (1) (a) notice has been given to the Medical Officer of Health specified in the direction, at least 7 days before the date on which it is intended to manu‐ facture the exempted drug, of the time and place of the proposed manu‐ facture; and (b) the use of such controlled drug in the manufacture is supervised by an officer.
Custody of controlled drugs Subject to subclause (4), and to any conditions that may be imposed under regulation 3 or regulation 19, every person in possession, for the purposes of sale, or in the course of any profession, or in the course of carriage, or for the purposes of use in any ship, aircraft, or motor vehicle, of a controlled drug that is not required for immediate use shall— (a) (b) (c) keep it in a locked cupboard, or a locked compartment, that is construc‐ ted of metal or concrete or both, and that, in the case of any cupboard or compartment installed in a building after the commencement of these regulations, is of an approved type; and ensure that the cupboard or compartment is securely fixed to, or is part of, the building, ship, aircraft, or vehicle within which the controlled drug is kept for the time being; and ensure that the key of the cupboard or compartment is kept in a safe place when not being used.
Where the building, ship, aircraft, or vehicle within which the controlled drug is kept for the time being is left unat‐ tended, that safe place shall not be within that building, ship, aircraft, or vehicle: provided that this paragraph shall not apply if the cupboard or compart‐ ment is fitted with a combination lock and is of an approved type.
(2) (3) In paragraph (a) and paragraph (c) of subclause (1) approved type means a type that, at the date of installation, has, for the time being been approved by the Medical Officer of Health after consultation with such constable as may be charged at that date with the function of advising the Medical Officer of Health for the purposes of that paragraph.
Subject to subclause (4), no person in possession, in circumstances to which subclause (1) applies, of a controlled drug that is kept for the time being within any building, ship, aircraft, or vehicle, shall leave that building, ship, aircraft, or vehicle unattended, unless he or she has taken all reasonable steps to secure that building, ship, aircraft, or vehicle, and the part of it in which the controlled drug is kept, against unlawful entry.
(4) Nothing in this regulation shall apply with respect to— 31 Part 4 r 28 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 (a) (b) (c) (d) (e) (f) (f) an exempted drug: any of the following preparations, namely: codeine phosphate syrup: codeine phosphate linctus: pholcodine linctus: pholcodine linctus, strong: [Revoked] any controlled drug for the time being named or described in Part 5 of Schedule 3 of the Act: a preparation of pseudoephedrine as described in paragraph (b) of the definition of partially exempted drug: tramadol.
[Revoked] (4AAA) [Revoked] (4A) This regulation does not apply in respect of the possession of a product by a person who holds a licence to operate a pharmacy under the Medicines Act 1981 if the product— (a) (b) (c) (d) contains cannabidiol; and contains no more than 27 milligrams of tetrahydrocannabinol per millili‐ tre of the product; and has consent for distribution under the Medicines Act 1981; and requires refrigeration to ensure its efficacy.
(5) For the purposes of subclauses (1) and (3), building includes a room in a build‐ ing: provided that a room shall be deemed to be attended— (a) (b) (c) in the case of a room forming part of a dwelling (being residential accommodation occupied by 1 person living alone, or by 2 or more per‐ sons living together but independently of other persons, if any, residing in or using other rooms in the same building) so long as a person who lives in that dwelling is within that dwelling or on adjacent land occu‐ pied or used in connection therewith; or in any other case, so long as a person who works in or otherwise uses that room is within another room communicating therewith; or in any case, if the room, and any room communicating therewith, is not vacated for a longer period than 10 minutes at any one time by all per‐ sons working in or otherwise using the room.
(6) [Revoked] 32 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 5 r 29 Regulation 28(1)(c) proviso: inserted, on 3 January 1980, by regulation 4(1) of the Misuse of Drugs Regulations 1977, Amendment No 3 (SR 1979/274).

Regulation 28(2): amended, on 1 October 2008, pursuant to section 116(a)(ii) of the Policing Act 2008 (2008 No 72).

Regulation 28(2): amended, on 3 January 1980, by regulation 4(2) of the Misuse of Drugs Regula‐ tions 1977, Amendment No 3 (SR 1979/274).
Regulation 28(4): replaced, on 1 June 1977, by regulation 3(1) of the Misuse of Drugs Regulations 1977, Amendment No 1 (SR 1977/135).

Regulation 28(4)(c): revoked, on 11 October 2001, by regulation 11 of the Misuse of Drugs Amend‐ ment Regulations 2001 (SR 2001/231).

Regulation 28(4)(d): inserted, on 19 May 1978, by regulation 3(1) of the Misuse of Drugs Regula‐ tions 1977, Amendment No 2 (SR 1978/142).
Regulation 28(4)(e): inserted, on 15 October 2004, by regulation 7 of the Misuse of Drugs (Ephe‐ drine and Pseudoephedrine) Amendment Regulations 2004 (SR 2004/315).

Regulation 28(4)(f): inserted, on 15 December 2022, by regulation 5 of the Misuse of Drugs (Fen‐ tanyl and Tramadol) Amendment Regulations 2022 (SL 2022/36).

Regulation 28(4)(f): revoked, on 5 May 2022, by regulation 21 of the Misuse of Drugs (Drug and Substance Checking Service Providers) Regulations 2022 (SL 2022/93).
Regulation 28(4AAA): revoked, on 5 May 2022, by regulation 21 of the Misuse of Drugs (Drug and Substance Checking Service Providers) Regulations 2022 (SL 2022/93).

Regulation 28(4A): inserted, on 7 September 2017, by regulation 7(2) of the Misuse of Drugs Amendment Regulations 2017 (LI 2017/198).

Regulation 28(6): revoked, on 19 May 1978, by regulation 3(2) of the Misuse of Drugs Regulations 1977, Amendment No 2 (SR 1978/142).
Part 5 Prescriptions for controlled drugs 29 General requirements in relation to prescriptions (1) A prescription for the supply of a controlled drug that is intended for human use and that is a Class A controlled drug, a Class B controlled drug, or a speci‐ fied Class C controlled drug must be— (a) (b) issued in a paper form that is provided by the Director-General and is completed in the handwriting of the controlled drug prescriber; or issued in an electronic form that is completed by the controlled drug pre‐ scriber using an approved system and is transmitted through that system.
(1A) [Revoked] (2) Notwithstanding subclause (1), a prescription for the supply of methadone issued by a medical practitioner, nurse practitioner, or designated prescriber nurse working in a place for the time being specified by the Minister under section 24(7)(b) of the Act may also be in any paper or electronic form approved by the Director-General.
(3) A prescription for the supply of a Class C controlled drug, other than a speci‐ fied Class C controlled drug, must be— 33 Part 5 r 29 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 (a) (b) issued in a paper form; or issued in an electronic form that is completed by the controlled drug pre‐ scriber using an approved system and is transmitted through that system.
(4) Every prescription for a controlled drug must— (a) (b) (c) (d) (e) (f) (g) (h) (i) (j) (k) (l) [Revoked] [Revoked] be dated with the date on which it was issued; and set out the address of the controlled drug prescriber; and set out the surname, initials of the first names, and address of— (i) (ii) the person to whom the controlled drug is intended to be adminis‐ tered; or the person who has custody of the animal to which the controlled drug is intended to be administered; and if it is for a person who is under the age of 12 years, set out in words the age in years and months of that person; and include the words “for dental treatment only”, if issued by a dentist; and include the words “for midwifery use only”, if issued by a midwife; and include the words “for animal treatment only”, if issued by a veterinar‐ ian; and set out the name of the controlled drug to be supplied; and not be in cipher, or abbreviated, otherwise than by abbreviations recog‐ nised in the British Pharmacopoeia, the British Pharmaceutical Codex, or other standard reference books on materia medica or pharmacy; and indicate the total amount of the controlled drug that may be sold or dis‐ pensed on the 1 occasion, or on each of the several occasions, authorised by that prescription; and (m) set out the dose and frequency of the dose, or, in the case of a controlled drug for external use, directions for use; and (n) where it prescribes an unusual dose, or what may be regarded as a dan‐ gerous dose, of any controlled drug, have the amount of the dose emphasised,— (i) in a paper form, by being underlined, with the initials of the con‐ trolled drug prescriber set out in the margin opposite; or (ii) in an electronic form, as required by the approved system.
(4A) In addition, every prescription for a controlled drug in paper form must— be legible and indelible; and be signed physically by the controlled drug prescriber in their own hand‐ writing.
(a) (b) 34 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 5 r 29 (4B) Any reference in these regulations that relates to including or recording any‐ thing in or on a prescription means, for an electronic prescription, including or recording it in the electronic records for the electronic prescription.
(5) In this regulation,— approved system means a system approved by the Director-General by notice in the Gazette specified Class C controlled drug— (a) means— (i) (ii) a drug that is amobarbital, amobarbital sodium, buprenorphine, butobarbitone, glutethimide, ketamine, secobarbital, or secobarbi‐ tal sodium; or a combination of 2 or more of the substances specified in subpara‐ graph (i); but (b) does not include any substance referred to in paragraph (a)(i), or any combination of substances referred to in paragraph (a)(ii), if that sub‐ stance or combination of substances is combined with any other pharma‐ cologically active substance or substances that are not listed in clause 1 of Part 4 of Schedule 3 of the Act.
(6) This regulation does not apply— (a) to a prescription for a controlled drug communicated under regulation 34(1); or (b) in respect of an exempted drug or partially exempted drug.

Regulation 29: replaced, on 1 July 2014, by regulation 9 of the Misuse of Drugs Amendment Regula‐ tions 2014 (LI 2014/199).

Regulation 29(1)(a): replaced, on 22 December 2022, by regulation 9(1) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
Regulation 29(1)(b): replaced, on 22 December 2022, by regulation 9(1) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 29(1A): revoked, on 18 December 2018, by section 12(6) of the Misuse of Drugs (Medic‐ inal Cannabis) Amendment Act 2018 (2018 No 54).

Regulation 29(2): amended, on 22 December 2022, by regulation 9(2)(a) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
Regulation 29(2): amended, on 22 December 2022, by regulation 9(2)(b) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 29(2): amended, on 31 January 2018, by section 8(3) of the Misuse of Drugs Amendment Act 2016 (2016 No 80).

Regulation 29(3): replaced, on 22 December 2022, by regulation 9(3) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
Regulation 29(4)(a): revoked, on 22 December 2022, by regulation 9(4) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 29(4)(b): revoked, on 22 December 2022, by regulation 9(4) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

35 Part 5 r 30 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 Regulation 29(4)(c): amended, on 22 December 2022, by regulation 9(5) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
Regulation 29(4)(d): amended, on 22 December 2022, by regulation 9(6) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 29(4)(g): amended, on 22 December 2022, by regulation 9(7)(a) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 29(4)(g): amended, on 22 December 2022, by regulation 9(7)(b) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
Regulation 29(4)(h): amended, on 22 December 2022, by regulation 9(7)(a) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 29(4)(h): amended, on 22 December 2022, by regulation 9(7)(b) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 29(4)(i): amended, on 22 December 2022, by regulation 9(7)(a) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
Regulation 29(4)(i): amended, on 22 December 2022, by regulation 9(7)(b) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 29(4)(n): replaced, on 22 December 2022, by regulation 9(8) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 29(4A): inserted, on 22 December 2022, by regulation 9(9) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
Regulation 29(4B): inserted, on 22 December 2022, by regulation 9(9) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
30 (1) Exemption for certain prescriptions This regulation applies if there is imposed on a licence a condition prohibiting the acquisition of controlled drugs otherwise than pursuant to the prescription of— (a) (b) (c) a controlled drug prescriber; or a named controlled drug prescriber; or a controlled drug prescriber belonging to a particular class of controlled drug prescribers.
(2) The following regulations do not apply to the extent that they are inconsistent with the terms of the licence in respect of anything done for the purpose of enabling compliance with the condition imposed on the licence: (a) (b) regulation 21(2) to (5E): regulation 29(4)(e), (f), (g), (h), (i), (m), and (n).

Regulation 30: replaced, on 1 July 2014, by regulation 10 of the Misuse of Drugs Amendment Regu‐ lations 2014 (LI 2014/199).
Regulation 30(2)(a): amended, on 5 October 2023, by regulation 5 of the Misuse of Drugs Amend‐ ment Regulations (No 2) 2023 (SL 2023/231).
31 Restrictions on supply on prescription (1) A person may not supply a controlled drug on a prescription— (a) more than once on that same prescription; or 36 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 5 r 31 (b) more than 7 days after the date of the prescription, in the case of a Class A controlled drug or a Class B controlled drug; or (c) more than 6 months after the date of the prescription, in the case of a Class C controlled drug; or (d) in a quantity that, having regard to the dose and frequency of dose or the directions given by the controlled drug prescriber, is greater than a quan‐ tity sufficient for use for a period of 1 month.
(2) Subclause (1) is subject to regulation 31A.

(3) A person may not supply a controlled drug on an oral prescription more than once before receiving the confirmation of that prescription under regulation 34(4).
(4) On the first occasion of dispensing a prescription or, in the case of an oral pre‐ scription, on receipt of the confirmation of that prescription, there must be recorded in or on the prescription— (a) (b) the name of the proprietor of the business at which the prescription is dispensed; and the address of the premises from which the prescription is dispensed; and (c) the date on which the prescription is dispensed.
(5) On every subsequent occasion of dispensing a prescription, there must be recorded in or on the prescription— (a) (b) (c) the name of the proprietor of the business at which the prescription is dispensed; and the address of the premises from which the prescription is dispensed; and the date on which the prescription, or any indicated part or portion of the prescription, is dispensed.
(5A) If information is recorded on a paper prescription— (a) (b) under subclause (4), it must be written or stamped on the face or back of the prescription, above the signature of the controlled drug prescriber, in a manner and place that does not obscure any details of the prescription: under subclause (5), it must be written or stamped on the face or back of the prescription, in a manner and place that does not obscure any details of the prescription.
(6) In this regulation, oral prescription means a prescription communicated under regulation 34(1).

Regulation 31: replaced, on 1 July 2014, by regulation 11 of the Misuse of Drugs Amendment Regu‐ lations 2014 (LI 2014/199).

Regulation 31(3): amended, on 22 December 2022, by regulation 11(1) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
37 Part 5 r 31A Misuse of Drugs Regulations 1977 Version as at 5 October 2023 Regulation 31(4): amended, on 22 December 2022, by regulation 11(2) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 31(5): amended, on 22 December 2022, by regulation 11(3) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 31(5A): inserted, on 22 December 2022, by regulation 11(4) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
31A Exceptions to restrictions in regulation 31(1) Medical or nurse practitioners: prescriptions for Class A controlled drugs (1) A medical practitioner or nurse practitioner who issues a prescription for a Class A controlled drug may direct in the prescription that the drug be supplied on 2 occasions at a specified interval, with— (a) (b) the first occasion being not more than 7 days after the date of prescrip‐ tion; and the second occasion being not more than 7 days after the termination of that interval.
(2) In the case of a controlled drug supplied pursuant to a direction under sub‐ clause (1), the total quantity supplied, having regard to the dose and frequency of dose or the directions of the medical practitioner or nurse practitioner, must not be greater than a quantity sufficient for use for a period of 1 month.
Prescriptions for Class B or Class C controlled drugs (3) A medical practitioner, nurse practitioner, designated prescriber nurse, designa‐ ted prescriber pharmacist, midwife, or dentist who issues a prescription for a non-opioid Class B or Class C controlled drug may direct in the prescription that the drug be supplied on 3 or more occasions, which must be at monthly or shorter intervals.
(4) In the case of a non-opioid controlled drug supplied under a direction under subclause (3), the total quantity supplied, having regard to the dose and fre‐ quency of dose or the directions of the medical practitioner, nurse practitioner, designated prescriber nurse, designated prescriber pharmacist, midwife, or den‐ tist, must not be greater than a quantity sufficient for use for a period of 3 months.
Midwives: prescriptions for controlled drugs in Schedule 1C (5) A midwife who issues a prescription for a controlled drug specified in Sched‐ ule 1C may direct in the prescription that the drug be supplied on 2 occasions at a specified interval, with— (a) (b) the first occasion being not more than 4 days after the date of the pre‐ scription; and the second occasion being not more than 4 days after the termination of that interval.
In the case of a controlled drug supplied pursuant to a direction under sub‐ clause (5), the total quantity supplied, having regard to the dose and frequency (6) 38 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 5 r 31A of dose or the directions of the midwife, must not be greater than a quantity sufficient for use for a period of 1 month.
(6A) [Revoked] (6B) [Revoked] (7) (8) Certain controlled drug prescribers: prescriptions to protect patients or limit quantities in possession If, for special reasons relating to the protection of the patient, or for the purpose of limiting the quantity of any controlled drug in the possession of any person, the controlled drug prescriber (not being a dentist or veterinarian) who issues a prescription directs in the prescription that the controlled drug is to be dis‐ pensed daily or at such other regular intervals as the controlled drug prescriber considers necessary for a specified period not exceeding 3 months, the con‐ trolled drug may be supplied on not more than the number of occasions indica‐ ted, and not more frequently than the intervals directed.
Supply by authorised persons to restricted persons If a Medical Officer of Health has issued to a person a notice under section 25 of the Act that authorises him or her to supply a controlled drug for a restricted person on more than 2 occasions on any prescription, that person may supply the controlled drug in such quantity, at such frequency, and for such period as the notice specifies.
Regulation 31A: inserted, on 1 July 2014, by regulation 11 of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).

Regulation 31A(1) heading: inserted, on 22 December 2022, by regulation 12(1) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 31A(1) heading: amended, on 5 October 2023, by regulation 6(1) of the Misuse of Drugs Amendment Regulations (No 2) 2023 (SL 2023/231).
Regulation 31A(1): amended, on 5 October 2023, by regulation 6(2) of the Misuse of Drugs Amend‐ ment Regulations (No 2) 2023 (SL 2023/231).

Regulation 31A(1): amended, on 22 December 2022, by regulation 12(2)(a) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 31A(1): amended, on 22 December 2022, by regulation 12(2)(b) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
Regulation 31A(2): amended, on 18 December 2018, by section 12(7) of the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 (2018 No 54).

Regulation 31A(3) heading: replaced, on 5 October 2023, by regulation 6(3) of the Misuse of Drugs Amendment Regulations (No 2) 2023 (SL 2023/231).

Regulation 31A(3): replaced, on 5 October 2023, by regulation 6(3) of the Misuse of Drugs Amend‐ ment Regulations (No 2) 2023 (SL 2023/231).
Regulation 31A(4): replaced, on 5 October 2023, by regulation 6(3) of the Misuse of Drugs Amend‐ ment Regulations (No 2) 2023 (SL 2023/231).

Regulation 31A(5) heading: inserted, on 22 December 2022, by regulation 12(4) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 31A(5): amended, on 22 December 2022, by regulation 12(2)(a) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
39 Part 5 r 32 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 Regulation 31A(5): amended, on 22 December 2022, by regulation 12(2)(b) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 31A(6A) heading: revoked, on 5 October 2023, by regulation 6(4) of the Misuse of Drugs Amendment Regulations (No 2) 2023 (SL 2023/231).

Regulation 31A(6A): revoked, on 5 October 2023, by regulation 6(4) of the Misuse of Drugs Amend‐ ment Regulations (No 2) 2023 (SL 2023/231).
Regulation 31A(6B): revoked, on 5 October 2023, by regulation 6(4) of the Misuse of Drugs Amend‐ ment Regulations (No 2) 2023 (SL 2023/231).

Regulation 31A(7) heading: inserted, on 22 December 2022, by regulation 12(5) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 31A(7): amended, on 22 December 2022, by regulation 12(6)(a) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
Regulation 31A(7): amended, on 22 December 2022, by regulation 12(6)(b) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 31A(7): amended, on 22 December 2022, by regulation 12(6)(c) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 31A(8) heading: inserted, on 22 December 2022, by regulation 12(7) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
32 Verification of prescriptions (1) No person may supply a controlled drug pursuant to a paper prescription pur‐ porting to be signed by a controlled drug prescriber, with whose signature the person is not acquainted, until the person has satisfied himself or herself that the signature is genuine.
(2) No person may— (a) (b) alter any paper or electronic prescription appearing to be signed or issued by a controlled drug prescriber that purports to authorise the sup‐ ply of any controlled drug; or alter any paper or electronic prescription in such a manner that it pur‐ ports to authorise the supply of any controlled drug.
(3) However, subclause (2) does not apply to a controlled drug prescriber who, after signing a paper prescription, alters that prescription in his or her own handwriting and then signs the prescription again beside the alteration.
(4) A person authorised to deal in controlled drugs must keep a prescription pur‐ porting to authorise the supply of a controlled drug and notify immediately the officer in charge of the nearest Police station or the Medical Officer of Health if the person believes on reasonable grounds,— (a) (b) for a paper prescription, that any signature purporting to be that of a con‐ trolled drug prescriber, and appearing on the prescription, is not genuine; or for a paper or electronic prescription, that the prescription has been altered by an unauthorised person.
40 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 5 r 33 Regulation 32: replaced, on 11 October 2001, by regulation 15 of the Misuse of Drugs Amendment Regulations 2001 (SR 2001/231).

Regulation 32(1): amended, on 22 December 2022, by regulation 13(1) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 32(1): amended, on 1 July 2014, by regulation 12(1) of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).
Regulation 32(2)(a): amended, on 22 December 2022, by regulation 13(2) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 32(2)(a): amended, on 22 December 2022, by regulation 13(3) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 32(2)(a): amended, on 1 July 2014, by regulation 12(2) of the Misuse of Drugs Amend‐ ment Regulations 2014 (LI 2014/199).
Regulation 32(2)(b): amended, on 22 December 2022, by regulation 13(2) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 32(3): replaced, on 1 July 2014, by regulation 12(3) of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).

Regulation 32(3): amended, on 22 December 2022, by regulation 13(4) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
Regulation 32(4): amended, on 22 December 2022, by regulation 13(5) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 32(4)(a): amended, on 22 December 2022, by regulation 13(6) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 32(4)(a): amended, on 1 July 2014, by regulation 12(1) of the Misuse of Drugs Amend‐ ment Regulations 2014 (LI 2014/199).
Regulation 32(4)(b): amended, on 22 December 2022, by regulation 13(7) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

33 Retention of paper prescriptions (1) No person shall supply any controlled drug (other than a Class C controlled drug) pursuant to any paper prescription except on condition that the prescrip‐ tion is retained by him or her.
(2) Every person so supplying any such controlled drug shall retain the prescrip‐ tion for a period of 4 years from the date on which the controlled drug is sup‐ plied, or, if the controlled drug is supplied pursuant to the same prescription on more than 1 occasion, from the last of the dates on which it is so supplied.
All such prescriptions shall be retained on the premises in an orderly and consecu‐ tive manner, and shall at all times be available to any constable or any officer, who may inspect them and make copies thereof: provided that, if the proprietor of the business from which the controlled drug was supplied vacates those premises, the prescriptions shall be stored at such place as is approved in writing by the Medical Officer of Health for the pur‐ pose.
Regulation 33 heading: amended, on 22 December 2022, by regulation 14(1) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 33(1): amended, on 22 December 2022, by regulation 14(2) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

41 Part 5 r 34 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 Section 33(2): amended, on 1 October 2008, pursuant to section 116(a)(ii) of the Policing Act 2008 (2008 No 72).
34 (1) Emergencies In the case of an emergency, a prescriber may communicate orally or by tele‐ phone a prescription for a controlled drug to a pharmacist who personally knows the prescriber (an oral prescription).

(2) A pharmacist may supply a controlled drug to any person on an oral prescrip‐ tion.
(3) Immediately after communicating an oral prescription, a prescriber must— (a) issue a prescription in paper or electronic form in accordance with the requirements of regulation 29 confirming the oral prescription; and (b) include in the prescription— (i) a statement to the effect that the prescription is intended only as confirmation of the oral prescription; and (ii) the date of the oral prescription.
(4) Not later than 2 business days after the date of the oral prescription, the pre‐ scriber must deliver the paper prescription, or transmit the electronic prescrip‐ tion, to the pharmacist to whom the oral prescription was communicated.
(5) After delivery or transmission of the prescription in accordance with subclause (4), the prescription and the pharmacist are subject to all provisions in these regulations relating to prescriptions for the supply of controlled drugs and to the duties of persons in respect of such prescriptions.
(6) In this regulation, prescriber means any of the following persons: (a) (b) (c) (d) (e) a medical practitioner: a nurse practitioner: a midwife: a designated prescriber nurse: a designated prescriber pharmacist.

Regulation 34: replaced, on 1 July 2014, by regulation 13 of the Misuse of Drugs Amendment Regu‐ lations 2014 (LI 2014/199).

Regulation 34(3)(a): amended, on 22 December 2022, by regulation 15(1) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
Regulation 34(3)(b): amended, on 22 December 2022, by regulation 15(2) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 34(4): amended, on 22 December 2022, by regulation 15(3) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 34(5): amended, on 22 December 2022, by regulation 15(4) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
42 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 5 r 35 35 (1) (2) (3) (4) Duty to supply information Every controlled drug prescriber must answer in writing, to the best of his or her knowledge and belief, any questions addressed to him or her by the Med‐ ical Officer of Health with respect to his or her prescribing, administering, or supplying controlled drugs and in respect of the identification of the person for whom they were prescribed or to whom they were administered or supplied.
Every person who supplies a controlled drug (not being a Class C controlled drug) on the prescription of a controlled drug prescriber must ensure that the Medical Officer of Health is advised, within 1 month after the date of the sup‐ ply, of— (a) (b) (c) (d) (e) the name and address of the person for whom the controlled drug is sup‐ plied: the name and address of the controlled drug prescriber: the date of the prescription: the name or description of the controlled drug supplied: the amount of the controlled drug supplied on the occasion or on each of the occasions of supply: (f) each date on which the controlled drug is supplied.
It shall be sufficient compliance with the requirements of subclause (2) if the person supplying the controlled drug provides the Medical Officer of Health, within 1 month after the date of the supply or, if the prescription authorises the supply of a controlled drug on more occasions than 1, the date of the first sup‐ ply, with a copy of the prescription to which the supply relates.
In this regulation, prescription includes any written authority, order, or request for the supply of controlled drugs signed by a controlled drug prescriber, not being an authority, order, or request relating to a disposal by wholesale within the meaning of regulation 47; and prescribing has a corresponding meaning: provided that subclause (2)(a) shall not apply to any such authority, order, or request not having reference to a particular patient.
Regulation 35(1): amended, on 1 July 2014, by regulation 14(1) of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).

Regulation 35(1): amended, on 7 September 1990, by regulation 8(b) of the Misuse of Drugs Regula‐ tions 1977, Amendment No 9 (SR 1990/222).

Regulation 35(2): replaced, on 1 July 1993, by regulation 8(1) of the Misuse of Drugs Regulations 1977, Amendment No 10 (SR 1993/157).
Regulation 35(2): amended, on 1 July 2014, by regulation 14(2) of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).

Regulation 35(2)(b): replaced, on 1 July 2014, by regulation 14(3) of the Misuse of Drugs Amend‐ ment Regulations 2014 (LI 2014/199).

Regulation 35(4): amended, on 1 July 2014, by regulation 14(4)(a) of the Misuse of Drugs Amend‐ ment Regulations 2014 (LI 2014/199).
43 Part 5 r 36 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 Regulation 35(4): amended, on 1 July 2014, by regulation 14(4)(b) of the Misuse of Drugs Amend‐ ment Regulations 2014 (LI 2014/199).

Regulation 35(4): amended, on 1 July 1993, by regulation 8(2) of the Misuse of Drugs Regulations 1977, Amendment No 10 (SR 1993/157).
36 Special provisions for hospitals (1) Where a controlled drug is required for the treatment of a patient for the time being maintained in a hospital or other institution, the medical practitioner, nurse practitioner, midwife, designated prescriber nurse, or designated pre‐ scriber pharmacist attending the patient may, instead of issuing a prescription, enter on the patient’s chart, or other clinical record appertaining to the patient, the particulars required by regulation 29(4)(c), (j), and (m), in the manner required and subject to the limitations imposed by regulation 29(4)(k) and (n) and (4A)(a) and (b), and such entry shall have the same effect as a prescription.
(2) In the case of a maternity hospital, the medical superintendent, if any, may gen‐ erally, and any medical practitioner, nurse practitioner, midwife, designated prescriber nurse, or designated prescriber pharmacist attending a patient may in relation to any patient or patients attended by him or her, by an instruction in writing recorded in a book set aside for the purpose containing the same par‐ ticulars and written in the like manner as are required in the case of an entry under subclause (1), authorise the administration, in the absence of complica‐ tions requiring the presence of a medical practitioner or midwife, of a con‐ trolled drug (being a controlled drug that, if there is no medical superintendent of the hospital, the manager of the hospital is authorised to possess) to a mater‐ nity patient between the commencement and the termination of labour.
(3) Every instruction given under subclause (2) shall cease to have effect on the expiration of 6 months from the date on which it is given or renewed, as the case may require.

Regulation 36(1): amended, on 22 December 2022, by regulation 16(a) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Regulation 36(1): amended, on 22 December 2022, by regulation 16(b) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
Regulation 36(1): amended, on 1 July 2014, by regulation 15 of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).

Regulation 36(1): amended, on 11 October 2001, by regulation 18(1) of the Misuse of Drugs Amend‐ ment Regulations 2001 (SR 2001/231).

Regulation 36(2): amended, on 1 July 2014, by regulation 15 of the Misuse of Drugs Amendment Regulations 2014 (LI 2014/199).
Regulation 36(2): amended, on 18 September 2004, by section 175(3) of the Health Practitioners Competence Assurance Act 2003 (2003 No 48).

Regulation 36(2): amended, on 11 October 2001, by regulation 18(2) of the Misuse of Drugs Amend‐ ment Regulations 2001 (SR 2001/231).

Regulation 36(2): amended, on 7 September 1990, by regulation 9(a) of the Misuse of Drugs Regula‐ tions 1977, Amendment No 9 (SR 1990/222).
Regulation 36(2): amended, on 7 September 1990, by regulation 9(b) of the Misuse of Drugs Regula‐ tions 1977, Amendment No 9 (SR 1990/222).
44 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 6 r 38 Part 6 Registers, records, and returns 37 (1) Pharmacists and dispensing practitioners This regulation shall apply to every person authorised by or under these regula‐ tions to deal in controlled drugs who is— (a) (b) a pharmacist; or a practitioner who dispenses his or her own medicines but does not deal in any controlled drug except by supply or administration to patients or animals under his or her care and by the compounding and dispensing of prescriptions containing controlled drugs; or (c) a person who is licensed to supply controlled drugs on prescription.
(2) Subject to these regulations, every person to whom this regulation applies shall keep— (a) a Controlled Drugs Register consisting of a bound volume of consecu‐ tively numbered pages in form 1 of Schedule 1, in which each page shall have entries relating only to 1 form of 1 controlled drug: (b) a Prescription Book described in subclause (3).
(3) The Prescription Book shall be a bound volume in which shall be entered a separate record of every prescription dispensed (including any repeated pre‐ scription) that contains any portion of a controlled drug showing— (a) (b) (c) (d) the surname, initials of the first names, and address of the person for whose use the controlled drug is intended: the surname, initials of the first names, and address of the person pre‐ scribing the controlled drug: the proportion and total amount of the controlled drug so dispensed: the date on which the controlled drug was delivered to the person for whose use it was dispensed or to some other authorised person on his or her behalf.
(4) In the case of every pharmacy, the Controlled Drugs Register and the Prescrip‐ tion Book kept under subclause (2) shall be retained continuously, subject to regulation 42, on the premises as a permanent record of the business carried on there.

Regulation 37(4): amended, on 18 September 2004, by section 175(3) of the Health Practitioners Competence Assurance Act 2003 (2003 No 48).
38 Other dealers Every person who is licensed to deal in or to possess controlled drugs shall keep, in any premises at which he or she is licensed to deal in or possess con‐ trolled drugs, a Controlled Drugs Register in form 1 of Schedule 1 in the man‐ ner required by regulation 37(2)(a).
45 Part 6 r 39 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 39 Form of records (1) Notwithstanding anything in subclause (2) or subclause (3) of regulation 37 or in regulation 38, the Director-General may, either generally or specially, by notice in the Gazette or by notice in writing to the person to whom it applies, approve the use of such loose-leaf or other systems of recording as may be spe‐ cified in the notice instead of the form of register or book prescribed by those provisions.
(2) 40 (1) The Director-General may at any time withdraw any such approval by notice given in the same manner as the notice of approval.
Entries in Controlled Drugs Register and Prescription Book Every person who is required under this Part to maintain a Controlled Drugs Register or a Prescription Book shall enter therein, legibly and indelibly, the particulars indicated in form 1 of Schedule 1 or in regulation 37(3), as the case may require, in relation to all controlled drugs dealt in, possessed, or dispensed by him or her; and the appropriate entries relating to any matter shall be made therein not later than the ordinary business day next following the day on which that matter arose.
(2) No person shall make or cause or permit to be made in any Controlled Drugs Register or Prescription Book any entry that is untrue in any particular, unless it is forthwith corrected as hereinafter provided, or obliterate, or cancel, or alter, or cause or permit to be obliterated, or cancelled, or altered, any entry made in any such register or book.

(3) Every person who is required under this Part to maintain a Controlled Drugs Register or a Prescription Book shall initial every entry made therein.
(4) Any mistake in any entry may be corrected by a marginal note or footnote giv‐ ing the correct particulars and containing, as part of the note, the date on which the note is written.

41 Exemption of practitioners (1) Notwithstanding anything in regulation 37, that regulation shall not bind any practitioner until he or she is notified by the Director-General in writing that that regulation shall apply in his or her case.
The Director-General may at any time withdraw any notification under sub‐ clause (1) and thereupon the said regulation 37 shall cease to bind that practi‐ tioner.
Retention of records Subject to the provisions of this Part, every person who is required to maintain a Controlled Drugs Register or a Prescription Book shall keep that register or book in a neat and orderly manner in some place of security at the premises at which he or she is for the time being authorised to deal in or possess controlled drugs or at such other place as may be approved from time to time by the (2) 42 (1) 46 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 6 r 43 Director-General, and shall so keep every such register or book for a period of 4 years following the date of the last entry made therein: provided that if he or she ceases to be so authorised he or she shall deliver every such register and book to, or deposit them at a place approved by, the Director-General for custody, or, after the expiration of the said period of 4 years, for destruction.
(2) Every person who is required to maintain a Controlled Drugs Register or Pre‐ scription Book shall at all times permit any constable or any officer to inspect that register or book and to make copies of any entries appearing therein.

Regulation 42(1): amended, on 19 May 1978, by regulation 4 of the Misuse of Drugs Regulations 1977, Amendment No 2 (SR 1978/142).

Regulation 42(2): amended, on 1 October 2008, pursuant to section 116(a)(ii) of the Policing Act 2008 (2008 No 72).
43 (1) Stocktaking Every person who is required to maintain a Controlled Drugs Register under this Part shall— (a) (b) as at the close of business on 30 June and 31 December in every year; and as at the date on which he or she transfers the stock in his or her posses‐ sion at the place where he or she carries on his or her profession, calling, or business to any other person,— record the actual stock of all controlled drugs in his or her possession at that date, and prepare a quantity stock account covering the period since the previ‐ ous stocktaking, and enter in the stock account a proper explanation of any variation between the calculated balance and the actual stock.
(2) The stock record, quantity stock account, and explanation of variations shall be entered on the page of the Controlled Drug Register appropriate to the con‐ trolled drug or form of controlled drug to which the information refers, and shall be completed within 14 days after the date as at which stock is taken.

(3) Where any person transfers his or her stock to another person the record of stock shall, as far as is practicable, be verified by the signatures of both such persons.
(4) An arrangement whereby a person who is authorised by or under these regula‐ tions to deal in a controlled drug carries on a practice or business on behalf of another person who is so authorised and who is temporarily absent therefrom, shall not constitute a transfer of stock within the meaning of this regulation, but in any such case the first-mentioned person shall, for the purposes of these regulations, be deemed to be the servant of the last-mentioned person in respect of that practice or business during the currency of that arrangement.
47 Part 6 r 44 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 44 (1) Hospital records Every manager or other person in charge of a hospital within the meaning of the Mental Health (Compulsory Assessment and Treatment) Act 1992 or the Hospitals Act 1957 or of an institution, in which a pharmacist is employed, shall ensure that records are kept at that hospital or institution in accordance with this regulation and regulations 45 and 46.
(2) Without limiting subclause (1), every chief pharmacist, or, if there is no chief pharmacist, such person on whom a duty is imposed by that subclause as the case may require, shall— (a) (b) keep a separate Main Controlled Drugs Register in form 1 of Schedule 1 in respect of each store and dispensary of the hospital or other institu‐ tion; and ensure that there is kept, in the like form, a Ward Book in respect of each ward of the hospital or other institution.
(3) In this regulation, and in regulation 45, chief pharmacist means a pharmacist employed in a hospital or other institution as a chief pharmacist or as a pharma‐ cist in charge of a dispensary or in a similar capacity.

Regulation 44(1): replaced, on 1 July 1993, by regulation 9 of the Misuse of Drugs Regulations 1977, Amendment No 10 (SR 1993/157).
45 Ward Books Every person upon whom the duty of ensuring that a Ward Book is kept is imposed by regulation 44(2) shall ensure that entries are made therein in accordance with the following requirements: (a) (b) (c) entries recording disposal shall be made immediately following the administration of the controlled drug: each Ward Book shall be kept posted by the charge nurse or person in charge of the ward; and the manager or other person in charge of the hospital or institution shall supervise the duties of that charge nurse or person in relation thereto: the Ward Book shall at all times show entries of receipts corresponding to entries of disposals in the appropriate Main Controlled Drugs Regis‐ ter; the said entries shall be made, at the time of the issue and receipt of the controlled drug, first in the Main Controlled Drugs Register (if any) and immediately afterwards in the Ward Book; the entries in both cases shall be signed by both the person receiving and the person issuing the controlled drug; and those persons shall be persons expressly authorised in that behalf by the manager or chief pharmacist or other person in charge, as the case may require: (d) once in every week the Ward Book shall be checked, and compared with any balance of the controlled drug on hand, jointly by the person in charge of the ward and the principal nurse, or the manager or other per‐ 48 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 6 r 47 son in charge, or the chief pharmacist, as the case may be, and the princi‐ pal nurse, manager, other person, or chief pharmacist shall indicate by signing their names and entering the date, that the checking has been so done.
Regulation 45: replaced, on 1 July 1993, by regulation 10 of the Misuse of Drugs Regulations 1977, Amendment No 10 (SR 1993/157).
46 Application of other regulations to hospital records Regulations 38, 39, 40, 42, 43, and 47 shall apply with any necessary modifica‐ tions to the persons and records to whom or which regulations 44 and 45 apply: provided that regulation 47 shall apply only in respect of controlled drugs dis‐ posed of from the store or dispensary of the hospital or other institution to a person outside that hospital or other institution.
47 (1) (2) Returns of wholesale transactions In this regulation disposal by wholesale means— (a) (b) export or supply by a person licensed under these regulations to deal in controlled drugs: supply to any person (other than a practitioner) who is authorised to use in manufacture, supply, or export controlled drugs or is licensed under regulation 9(1)(a), or is authorised by any of regulations 17 to 19, to pos‐ sess controlled drugs.
Every person who is authorised to supply controlled drugs shall, immediately upon the disposal by wholesale of any controlled drug, and in addition to any entry required by these regulations to be made in a register, enter in 2 docu‐ ments, each being in form 2 of Schedule 1 or in such other form as may be approved from time to time by the Director-General, the particulars relating to that disposal indicated in that form, and shall, within 7 days after the end of each month, forward one of those documents, verified by his or her signature or the signature of his or her employee, to the Medical Officer of Health: provided that— (a) where such disposal by wholesale is not a regular part of the business of that person, the information, instead of being recorded and furnished in the said form, may be recorded and furnished to the Medical Officer of Health in writing: (b) where the controlled drug is supplied with the intention that it shall be replaced within 15 days after the original transaction, it shall not be necessary for information of the transaction to be recorded in the said form, or furnished to the Medical Officer of Health, unless, on the expir‐ ation of the said period of 15 days, the said controlled drug has not been replaced by or on behalf of the person to whom it was supplied.
49 Part 6 r 48 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 Regulation 47(1)(b): amended, on 19 May 1978, by regulation 5(1) of the Misuse of Drugs Regula‐ tions 1977, Amendment No 2 (SR 1978/142).

Regulation 47(2): amended, on 10 March 1983, by regulation 3(2) of the Misuse of Drugs Regula‐ tions 1977, Amendment No 6 (SR 1983/19).

Regulation 47(2): amended, on 19 May 1978, by regulation 5(2) of the Misuse of Drugs Regulations 1977, Amendment No 2 (SR 1978/142).
48 Exemptions from Part 6 (1) Nothing in this Part shall apply in relation to the acquisition, possession, sup‐ ply, or administration of any Class C controlled drug by a person to whom any of section 8(1)(a), (b), and (f) of the Act applies.

(2) Nothing in this Part shall apply in respect of any exempted drug, or any con‐ trolled drug for the time being named or described in any of Parts 2 to 5 of Schedule 3 of the Act.
(3) [Revoked] Regulation 48(1): amended, on 22 December 2022, by regulation 17 of the Misuse of Drugs Amend‐ ment Regulations 2022 (SL 2022/303).

Regulation 48(2): replaced, on 3 January 1980, by regulation 5(1) of the Misuse of Drugs Regula‐ tions 1977, Amendment No 3 (SR 1979/274).

Regulation 48(3): revoked, on 18 December 2018, by section 12(8) of the Misuse of Drugs (Medici‐ nal Cannabis) Amendment Act 2018 (2018 No 54).
Part 7 Miscellaneous provisions 49 Notification of import and export of certain controlled drugs [Revoked] Regulation 49: revoked, on 11 October 2001, by regulation 19 of the Misuse of Drugs Amendment Regulations 2001 (SR 2001/231).
49A Notification of stock Every person who is licensed under these regulations to deal in any controlled drug for the time being named or described in Schedule 1 or Schedule 2 or Part 2 of Schedule 3 of the Act, or in any partially exempted drug shall, before 31 January in each year, notify the Medical Officer of Health of the amount of each such controlled drug held in stock by that person at 31 December of the preceding year, and the total amount of any such controlled drug used, during that preceding year, in the manufacture of an exempted drug.
Regulation 49A: inserted, on 22 September 1983, by regulation 3 of the Misuse of Drugs Regulations 1977, Amendment No 7 (SR 1983/174).

Regulation 49A: amended, on 15 October 2004, by regulation 8 of the Misuse of Drugs (Ephedrine and Pseudoephedrine) Amendment Regulations 2004 (SR 2004/315).
50 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Part 7 r 52A 50 (1) Restrictions on advertising Subject to subclauses (2) and (4), no person shall publish, or cause or permit to be published, any advertisement.
(2) Nothing in subclause (1) shall apply to any advertisement that is distributed only to practitioners or pharmacists, or that is contained in a publication that, in the ordinary course, circulates solely or mainly, or is distributed solely or mainly, to practitioners or pharmacists, and that— (a) (b) states the true name and address of the place of business of the person by whom or at whose request the advertisement is published; and contains a conspicuous statement sufficient to indicate that the advertise‐ ment relates to a controlled drug, or, if the advertisement is comprised in a price list or similar publication, contains the abbreviation “CD”.
(3) Every person who contravenes subclause (1) commits an offence against these regulations.

(4) Nothing in this regulation shall apply in respect of any exempted drug or any partially exempted drug.
51 Communications through Medical Officer of Health Except in the case of an application for a licence to import a controlled drug or for a licence to export a controlled drug or of a communication relating to any such application, every application, return, and other communication, required or intended to be made or delivered to the Director-General by any person under these regulations, shall be made through the Medical Officer of Health in charge of the health district in which are situated the premises to which the communication relates, or, if there are no such premises, in which the con‐ trolled drug to which the communication relates for the time being is or, at the material time, was or will be.
Regulation 51: amended, on 1 July 1993, by regulation 11 of the Misuse of Drugs Regulations 1977, Amendment No 10 (SR 1993/157).

Regulation 51: amended, on 22 September 1983, by regulation 4 of the Misuse of Drugs Regulations 1977, Amendment No 7 (SR 1983/174).
52 Penalty Every person who commits an offence against these regulations shall be liable to a fine not exceeding $500, and, where the offence is a continuing one, to a further fine not exceeding $20 for every day or part of a day during which the offence has continued.
52A Application of regulations to drug and substance checking service providers and their users (1) Regulations 23, 25, 28, 38, 47, 51, and 52 do not apply to a drug and substance checking service provider that is acting in the course of performing the service provider’s functions.
51 Part 7 r 53 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 (2) Regulations 23, 25, and 47 do not apply to an individual who is doing 1 or both of the following: (a) (b) supplying a controlled drug to a service provider for the purpose of checking: surrendering a controlled drug to a service provider for the purpose of disposal.

(3) Subclause (1) is subject to the conditions of the service provider’s licence.
Regulation 52A: inserted, on 5 May 2022, by regulation 22 of the Misuse of Drugs (Drug and Sub‐ stance Checking Service Providers) Regulations 2022 (SL 2022/93).

53 Transitional [Revoked] Regulation 53: revoked, on 16 June 2023, by regulation 7 of the Misuse of Drugs Amendment Regu‐ lations 2023 (SL 2023/129).

54 Revocations The regulations specified in Schedule 2 are hereby revoked.
52 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Schedule 1AAA Schedule 1AAA Transitional, savings, and related provisions Schedule 1AAA: inserted, on 16 June 2023, by regulation 8 of the Misuse of Drugs Amendment Regulations 2023 (SL 2023/129).

r 2A Part 1 Provision relating to Misuse of Drugs Amendment Regulations 2023 Schedule 1AAA Part 1: inserted, on 16 June 2023, by regulation 8 of the Misuse of Drugs Amend‐ ment Regulations 2023 (SL 2023/129).
1 Exemption from requirement in regulation 25(1) for fentanyl supplied before 1 July 2023 The requirement in regulation 25(1) for a label to display the appropriate desig‐ nation does not apply in respect of fentanyl supplied by a retailer, manufac‐ turer, or wholesaler before 1 July 2023.

Schedule 1AAA clause 1: inserted, on 16 June 2023, by regulation 8 of the Misuse of Drugs Amend‐ ment Regulations 2023 (SL 2023/129).
53 Schedule 1AA Misuse of Drugs Regulations 1977 Schedule 1AA Licence fees Version as at 5 October 2023 r 3(4) Schedule 1AA: inserted, on 21 August 2006, by regulation 7 of the Misuse of Drugs (Fees) Amend‐ ment Regulations 2006 (SR 2006/189).
1 2 3 4 Licence to deal in controlled drugs Licence to import controlled drugs Licence to export controlled drugs Licence to possess controlled drugs $ 945 190 190 945 54 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Schedule 1A Schedule 1A Controlled drugs that designated prescriber nurses may prescribe in certain circumstances Schedule 1A: replaced, on 20 September 2016, by regulation 4 of the Misuse of Drugs Amendment Regulations (No 2) 2016 (LI 2016/185).
r 12A(1)(a) Alprazolam Buprenorphine, transdermal only Buprenorphine with naloxone, sublingual only Clonazepam, for anxiety and panic disorder only Codeine Diazepam, oral only Dihydrocodeine Fentanyl, transdermal only Lorazepam Lormetazepam Methadone, oral only Morphine Nitrazepam Oxazepam Temazepam Tramadol Triazolam Zopiclone Schedule 1A Tramadol: inserted, on 1 October 2023, by regulation 18(2) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
Schedule 1A Zopiclone: inserted, on 1 July 2023, by regulation 18(1) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

55 Schedule 1B Misuse of Drugs Regulations 1977 Version as at 5 October 2023 Schedule 1B Controlled drugs that designated prescriber pharmacists may prescribe r 12A(1)(b) Schedule 1B: inserted, on 4 July 2013, by regulation 16 of the Misuse of Drugs Amendment Regula‐ tions 2013 (SR 2013/238).
Schedule 1B heading: amended, on 22 December 2022, by regulation 19(1) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).

Schedule 1B heading: amended, on 20 September 2016, by regulation 7 of the Misuse of Drugs Amendment Regulations 2016 (LI 2016/139).

A reference in this schedule to a substance is a reference to the substance in every compound, form, mixture, or preparation that is declared to be a controlled drug under the Act.
Alprazolam Buprenorphine Clobazam Clonazepam Codeine Diazepam Dihydrocodeine Diphenoxylate Fentanyl Hydromorphone Lorazepam Lormetazepam 13 Methadone 14 Midazolam 15 Morphine Nitrazepam Oxazepam Oxycodone Pethidine Phenobarbital Phentermine Pholcodine Temazepam Tetrahydrocannabinol when a Class B1 controlled drug 56 Misuse of Drugs Regulations 1977 Schedule 1B Version as at 5 October 2023 24A Tramadol 25 26 27 Triazolam Zolpidem Zopiclone Schedule 1B item 24A: inserted, on 1 October 2023, by regulation 19(3) of the Misuse of Drugs Amendment Regulations 2022 (SL 2022/303).
Schedule 1B item 26: inserted, on 1 July 2023, by regulation 19(2) of the Misuse of Drugs Amend‐ ment Regulations 2022 (SL 2022/303).

Schedule 1B item 27: inserted, on 1 July 2023, by regulation 19(2) of the Misuse of Drugs Amend‐ ment Regulations 2022 (SL 2022/303).
57 Schedule 1C Misuse of Drugs Regulations 1977 Schedule 1C Controlled drugs that midwives may prescribe Version as at 5 October 2023 r 12A(1)(c) Schedule 1C: inserted, on 1 July 2014, by regulation 16 of the Misuse of Drugs Amendment Regula‐ tions 2014 (LI 2014/199).

A reference in this schedule to a substance is a reference to the substance in every compound, form, mixture, or preparation that is declared to be a controlled drug under the Act.
1 2 3 4 Fentanyl Morphine Pethidine Tramadol Schedule 1C item 4: inserted, on 15 December 2022, by regulation 6 of the Misuse of Drugs (Fen‐ tanyl and Tramadol) Amendment Regulations 2022 (SL 2022/36).

58 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Schedule 1 1 e l u d e h c S 1 m r o F ) 2 ( 4 4 , ) 1 ( 0 4 , 8 3 , ) 2 ( 7 3 r r k o o B d r a W / r e t s i g e R s g u r D d e l l o r t n o C n i a M / r e t s i g e R s g u r D d e l l o r t n o C . )
( , d e s n e p s i d , ” g n i k a t k c o t s l a c i s y h P “ r e d r o r o n o i t p i r c s e r P : n o i t a r a l c e rD o e t a D ; d e i l p p u s n o s r e p f o s s e r d d a d n a r o ; t n e i t a p f o e m a N e m a N r o ; ; d e v i e c e r m o h w 59 Schedule 1 Misuse of Drugs Regulations 1977 Version as at 5 October 2023 h t i w e c n a d r o c c a n i d e d r a w r o f s i , ] h t n o m [ , . )
9 1 / 3 8 9 1 R S ( 6 o N t n e m d n e m A , ) 1 ( 3 n o i t a l u g e r y b , 3 8 9 1 h c r a M 0 1 n o , d e c a l p e r : 2 m r o f 1 e l u d e h c S .
) 2 ( 7 4 n o i t a l u g e r : e r u t a n g i S ] r e i l p p u s f o s s e r d d a d n a e m a n [ y B ] r a e y [ ] h t n o m [ f o h t n o m e h t r o F : s e g a p f o r e b m u n l a t o T : o N e g a P ) 2 ( 60 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Schedule 2 Schedule 2 Regulations revoked r 54 Narcotics Regulations 1966 (SR 1966/82) (Reprinted with Amendments Nos 1 to 4: SR 1974/253) Narcotics Regulations 1966, Amendment No 1 (SR 1967/173) Narcotics Regulations 1966, Amendment No 2 (SR 1968/179) Narcotics Regulations 1966, Amendment No 3 (SR 1971/123) Narcotics Regulations 1966, Amendment No 4 (SR 1973/100) Narcotics Regulations 1966, Amendment No 5 (SR 1976/70) Issued under the authority of the Legislation Act 2019.
Date of notification in Gazette: 10 March 1977.

P G Millen, Clerk of the Executive Council.

61 Notes Misuse of Drugs Regulations 1977 Version as at 5 October 2023 Notes 1 General This is a consolidation of the Misuse of Drugs Regulations 1977 that incorpor‐ ates the amendments made to the legislation so that it shows the law as at its stated date.
2 Legal status A consolidation is taken to correctly state, as at its stated date, the law enacted or made by the legislation consolidated and by the amendments.

This presump‐ tion applies unless the contrary is shown.

Section 78 of the Legislation Act 2019 provides that this consolidation, pub‐ lished as an electronic version, is an official version.

A printed version of legis‐ lation that is produced directly from this official electronic version is also an official version.
3 Editorial and format changes The Parliamentary Counsel Office makes editorial and format changes to con‐ solidations using the powers under subpart 2 of Part 3 of the Legislation Act 2019.

See also PCO editorial conventions for consolidations.
4 Amendments incorporated in this consolidation Misuse of Drugs Amendment Regulations (No 2) 2023 (SL 2023/231) Misuse of Drugs Amendment Regulations 2023 (SL 2023/129) Misuse of Drugs Amendment Regulations 2022 (SL 2022/303) Misuse of Drugs (Drug and Substance Checking Service Providers) Regulations 2022 (SL 2022/93): Part 3 Misuse of Drugs (Fentanyl and Tramadol) Amendment Regulations 2022 (SL 2022/36) Misuse of Drugs (Medicinal Cannabis) Regulations 2019 (LI 2019/321): regulations 87–89 Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 (2018 No 54): section 12 Misuse of Drugs Amendment Regulations 2017 (LI 2017/198) Misuse of Drugs Amendment Act 2016 (2016 No 80): section 8 Misuse of Drugs Amendment Regulations (No 2) 2016 (LI 2016/185) Misuse of Drugs Amendment Regulations 2016 (LI 2016/139) Misuse of Drugs Amendment Regulations 2014 (LI 2014/199) Misuse of Drugs Amendment Regulations 2013 (SR 2013/238) Medicines Amendment Regulations 2011 (SR 2011/245): regulation 30 Policing Act 2008 (2008 No 72): section 116(a)(ii) Misuse of Drugs (Fees) Amendment Regulations 2006 (SR 2006/189) Misuse of Drugs Amendment Regulations 2006 (SR 2006/164) Veterinarians Act 2005 (2005 No 126): section 95 Misuse of Drugs (Ephedrine and Pseudoephedrine) Amendment Regulations 2004 (SR 2004/315) 62 Version as at 5 October 2023 Misuse of Drugs Regulations 1977 Notes Health Practitioners Competence Assurance Act 2003 (2003 No 48): section 175(3) Health and Disability Services (Safety) Act 2001 (2001 No 93): section 58(3)
 Misuse of Drugs Amendment Regulations 2001 (SR 2001/231) Misuse of Drugs Regulations 1977, Amendment No 11 (SR 1995/75) Misuse of Drugs Regulations 1977, Amendment No 10 (SR 1993/157) Misuse of Drugs Regulations 1977, Amendment No 9 (SR 1990/222) Misuse of Drugs Regulations 1977, Amendment No 7 (SR 1983/174) Misuse of Drugs Regulations 1977, Amendment No 6 (SR 1983/19) Misuse of Drugs Regulations 1977, Amendment No 3 (SR 1979/274) Misuse of Drugs Regulations 1977, Amendment No 2 (SR 1978/142) Misuse of Drugs Regulations 1977, Amendment No 1 (SR 1977/135) Wellington, New Zealand: Published under the authority of the New Zealand Government—2023 63